Fuse Medical (FZMD) 10-K 6 Apr 18 2017 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2017	Mar. 26, 2018	Jun. 30, 2017
Document And Entity Information [Abstract]
Entity Registrant Name	Fuse Medical, Inc.
Entity Central Index Key	319,016
Document Type	10-K
Document Period End Date	Dec. 31, 2017
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Is Entity a Well-known Seasoned Issuer	No
Is Entity a Voluntary Filer	No
Is Entity's Reporting Status Current	Yes
Entity Filer Category	Smaller Reporting Company
Entity Public Float			$ 2,205,059
Entity Common Stock, Shares Outstanding		65,890,808
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2,017
Trading Symbol	FZMD

CONSOLIDATED BALANCE SHEETS

CONSOLIDATED BALANCE SHEETS - USD ($)	Dec. 31, 2017	Dec. 31, 2016
Current assets:
Cash and cash equivalents	$ 804,715	$ 778,447
Accounts receivable, net of allowance of $499,099 and $1,682,995, respectively	6,570,382	6,508,286
Inventories, net of allowance of $1,110,742 and $1,134,013, respectively	10,626,769	11,426,828
Prepaid expenses and other current assets	32,466	23,018
Total current assets	18,034,332	18,736,579
Property and equipment, net	16,895	14,747
Security deposit		3,822
Deferred tax asset	375,278
Goodwill	820,650	820,650
Total assets	19,247,155	19,575,798
Current liabilities:
Accounts payable	2,588,091	2,452,922
Accrued expenses	1,830,679	3,068,054
Notes payable - related parties	150,000	150,000
Revolving line of credit	3,415,351	3,305,347
Total current liabilities	7,984,121	8,976,323
Earn-out liability	19,244,543
Total liabilities	27,228,664	8,976,323
Commitments and contingencies
Stockholders’ equity (deficit):
Preferred stock, $0.01 par value; 20,000,000 shares authorized; no shares issued and outstanding
Common stock, $0.01 par value; 100,000,000 shares authorized; 69,158,308 issued and 65,890,808 outstanding at December 31, 2017 and 15,890,808 issued and outstanding at December 31, 2016	671,583	158,908
Additional paid-in capital	(8,653,092)	10,440,567
Total stockholders’ equity (deficit)	(7,981,509)	10,599,475
Total liabilities and stockholders’ equity (deficit)	$ 19,247,155	$ 19,575,798

CONSOLIDATED BALANCE SHEETS (Pa

CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($)	Dec. 31, 2017	Dec. 31, 2016
Statement Of Financial Position [Abstract]
Net of allowance, accounts receivable	$ 499,099	$ 1,682,995
Net of allowance, inventories	$ 1,110,742	$ 1,134,013
Preferred Stock Par Value	$ 0.01	$ 0.01
Preferred Stock Shares Authorized	20,000,000	20,000,000
Preferred Stock Shares Issued	0	0
Preferred Stock Shares Outstanding	0	0
Common Stock Par Value	$ 0.01	$ 0.01
Common Stock Shares Authorized	100,000,000	100,000,000
Common Stock Shares Issued	69,158,308	15,890,808
Common Stock Shares Outstanding	65,890,808	15,890,808

CONSOLIDATED STATEMENTS OF OPER

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Income Statement [Abstract]
Net revenues	$ 26,407,206	$ 25,666,650
Cost of revenues	14,582,416	11,256,887
Gross profit	11,824,790	14,409,763
Operating expenses
Selling, general, administrative and other	5,356,475	4,170,835
Commissions	5,641,122	7,056,430
Gain on disposal of property and equipment	(5,367)
Depreciation	14,521	19,091
Total operating expenses	11,006,751	11,246,356
Operating income	818,039	3,163,407
Other income (expense):
Interest expense	(161,669)	(146,921)
Extinguishment of debt	43,308
Total other income (expense)	(118,361)	(146,921)
Net income	$ 699,678	$ 3,016,486
Net income per common share - basic	$ 0.04	$ 0.42
Net income per common share - diluted	$ 0.04	$ 0.33
Weighted average number of common shares outstanding - basic	16,027,794	7,185,890
Weighted average number of common shares outstanding - diluted	19,473,553	9,214,606

CONSOLIDATED STATEMENT OF CHANG

CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIT) - USD ($)	Total	Common Stock [Member]	Additional Paid-In Capital [Member]	Retained Earnings [Member]
Beginning Balance, Amount at Dec. 31, 2015	$ 7,998,142	$ 68,908	$ 7,929,234
Beginning Balance, Shares at Dec. 31, 2015		6,890,808
Member contribution (successor)	775,949		775,949
Member distribution (successor)	(2,481,178)		(2,346,859)	$ (134,319)
Fuse capital, net	1,290,076	$ 90,000	4,082,243	(2,882,167)
Fuse capital, net, Shares		9,000,000
Net income	3,016,486			3,016,486
Ending Balance, Amount at Dec. 31, 2016	10,599,475	$ 158,908	10,440,567
Ending Balance, Shares at Dec. 31, 2016		15,890,808
Restricted stock awards granted	42,609	$ 12,675	29,934
Restricted stock awards granted, Shares		3,267,500
Purchase of CPM Medical Consultants, LLC	(19,244,543)	$ 500,000	(19,744,543)
Purchase of CPM Medical Consultants, LLC, Shares		50,000,000
Deferred tax asset	375,278		375,278
Member contribution (successor)	1,738,620		1,738,620
Member distribution (successor)	(2,192,626)		(1,492,948)	(699,678)
Net income	699,678			$ 699,678
Ending Balance, Amount at Dec. 31, 2017	$ (7,981,509)	$ 671,583	$ (8,653,092)
Ending Balance, Shares at Dec. 31, 2017		69,158,308

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Cash flows from operating activities:
Net income	$ 699,678	$ 3,016,486
Adjustments to reconcile net income to net cash provided by operating activities:
Amortization of debt discount		13,094
Share-based compensation	42,609
Depreciation	14,521	19,091
Gain on disposal of property and equipment	(5,067)
Extinguishment of debt	(43,308)
Changes in operating assets and liabilities:
Accounts receivable	(62,096)	995,785
Inventories, net	2,022,723	(139,993)
Prepaid expenses and other current assets	(9,448)	107
Security deposit	3,822
Accounts payable	178,477	(1,313,409)
Accrued expenses	(1,236,527)	199,177
Deferred rent	(848)
Net cash provided by operating activities	1,604,536	2,790,338
Cash flows from investing activities:
Purchases of property and equipment	(20,334)
Insurance settlement proceeds	8,732
Proceeds from reverse acquisition		655,390
Net cash (used in) provided by investing activities	(11,602)	655,390
Cash flows from financing activities:
Payments on line of credit	(15,580,346)	(14,118,720)
Borrowings on line of credit	15,690,350	13,208,210
Member contributions (successor)	273,044	375,210
Member distributions (successor)	(1,949,714)	(2,395,606)
Net cash used in financing activities	(1,566,666)	(2,930,906)
Net increase in cash and cash equivalents	26,268	514,822
Cash and cash equivalents - beginning of year	778,447	263,625
Cash and cash equivalents - end of year	804,715	778,447
Supplemental disclosure of cash flow information:
Cash paid for interest	139,507	150,762
Supplemental disclosure of noncash operating and financing activities:
Member contributions through reduction of accounts payable		25,000
Member contributions of inventory	1,465,576	375,739
Member distributions of inventory	$ 242,912	$ 85,572

Nature of Operations

Nature of Operations	12 Months Ended
	Dec. 31, 2017
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Nature of Operations	Note 1. Nature of Operations Overview The Company was initially incorporated in 1968 as Golf Rounds.com, Inc., a Florida corporation. During July 1999, GolfRounds, Inc. was re-domesticated to Delaware through a merger into its wholly-owned subsidiary GolfRounds.com, Inc. Change in Control Between the period July 2016 through October 2016, the Company obtained three loans in the aggregate amount of $150,000 in exchange for convertible promissory notes (the “Notes”) bearing 10% interest per annum, with principal due and payable, upon demand of the payee. The Notes were issued as follows: $100,000 to NC 143 Family Holdings, LP, a family limited partnership controlled by Mark W. Brooks (“NC 143”), the Company’s Chairman of the Board of Directors (the “Board”); and $50,000 to Reeg Medical Industries, Inc., an investment holding company owned and controlled by Christopher C. Reeg, the Company’s Chief Executive Officer (“RMI”, and together with NC 143, the “Investors”). The Investors have the sole discretion and right to convert all or any portion of the then unpaid principal and interest balance of the Notes into shares of the Company’s common stock at a conversion price of $0.08 per share. On December 19, 2016 (the “Change-in-Control Date”), the Company entered into a Stock Purchase Agreement (the “Stock Purchase Agreement”) by and between the Investors and the Company, pursuant to which NC 143 acquired 5 million shares of the Company’s common stock for a purchase price of $400,000 and RMI acquired 4 million shares of the Company’s common stock for a purchase price of $320,000 (collectively the “Investor Shares”), effective as of the Change-in-Control Date. Direct offering costs of the Company were $64,609 in connection with the offer and sale of the Investor Shares, and, net proceeds from the offer and sale of the Investor Shares were $655,391. CPM Acquisition On December 15, 2017, Fuse entered into an agreement with NC 143 pursuant to which Fuse would purchase all of the outstanding membership interests of CPM Medical Consultants, LLC (“CPM”) (the “CPM Acquisition Agreement” and such transaction, the “CPM Acquisition”). On December 29, 2017, Fuse completed the previously-announced the CPM Acquisition, pursuant to the CPM Acquisition Agreement by Fuse and NC 143, dated December 15, 2017, whereby the Fuse would purchase all of the outstanding membership interests of CPM. Fuse issued 50 million shares of its common stock, par value $0.01 per share in exchange for 100% of the outstanding membership interests of CPM, at an agreed-upon value of $0.20 per share of common stock. The effective date of the CPM acquisition was December 31, 2017 (the “Effective Date”). The CPM Acquisition provides for contingent payments, (Earn-Out”) to NC 143 subject to certain sales and profitability targets being met by the Company for years after 2017. Fuse was the legal acquirer and, for accounting purposes, CPM was deemed to have acquired our Company in the CPM Acquisition. CPM is the successor entity and becomes the reporting entity which combines Fuse at the Change-in-Control Date, with the assets and liabilities of both companies combined at historical cost. (see note 3) Nature of Business Fuse is a national distributor of medical devices, who provides a broad portfolio of internal and external fixation products; upper and lower extremity plating and total joint reconstruction; soft tissue fixation and augmentation for sports medicine procedures; spinal implants for trauma, degenerative disc disease, and deformity indications (collectively, “Orthopedic Implants”) and a wide array of osteo-biologics and regenerative tissue which include human allografts, substitute bone materials and tendons, as well as regenerative tissues and fluids (“Biologics”). All of our medical devices are approved by the U.S. Food and Drug Administration (“FDA”) for sale in the United States, and all of our Biologics suppliers are licensed tissue banks accredited by the American Association of Tissue Banks (“AATB”). The Company’s board portfolio of Orthopedic Implants and Biologics provide high-quality products to assist surgeons with positive patient outcomes and cost-effective solutions for its customers, which include hospitals, medical facilities, and sub-distributors. Fuse operates under exclusive and non-exclusive agreements with certain vendors and supply partners in the geographic territories the Company serves. Fuse continuously reviews and expands its product lines to ensure that they offer the most comprehensive, high-quality and cost-effective selection of Orthopedic Implants and Biologics so that the Company can be more relevant to its customer needs while continuing to grow its existing customer base.

Significant Accounting Policies

Significant Accounting Policies	12 Months Ended
	Dec. 31, 2017
Accounting Policies [Abstract]
Significant Accounting Policies	Principles of Consolidation The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary. Intercompany transactions have been eliminated in consolidation. Use of Estimates The preparation of the consolidated financial statements in accordance with generally accepted accounting principles in the United State, (“GAAP”). GAAP requires the Company’s management to make estimates and assumptions that affect the reported amounts in the consolidated financial statements. Actual results could differ from those estimates. Significant estimates in the accompanying consolidated financial statements include the allowances for doubtful accounts and contractual pricing, valuation of inventories, accrued commissions, the fair value calculation of stock based compensation, and fair value of Earn-Out liability. Earnings Per Share Basic net income per common share is calculated by dividing net income attributable to common stockholders by the weighted-average number of common shares outstanding during the period, without consideration of common stock equivalents. Shares of restricted stock are included in the basic weighted average number of common shares outstanding from the time they vest. Diluted net income per common share is computed by dividing net income attributable to common stockholders by the weighted-average number of common share equivalents outstanding for the period determined using the treasury stock method. As of December 31, 2017, 700,000 outstanding common stock equivalents have been included with diluted net earnings per share. As of December 31, 2017, and 2016, common stock equivalents included options to purchase 1,302,052 and 1,304,788 common shares, respectively. Fair Value Measurements Fair value is the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants. The Company classifies assets and liabilities recorded at fair value under the fair value hierarchy based upon the observability of inputs used in valuation techniques. Observable inputs (highest level) reflect market data obtained from independent sources, while unobservable inputs (lowest level) reflect internally developed market assumptions. The fair value measurements are classified under the following hierarchy: Level 1—Observable inputs that reflect quoted market prices (unadjusted) for identical assets and liabilities in active markets; Level 2—Observable inputs, other than quoted market prices, that are either directly or indirectly observable in the marketplace for identical or similar assets and liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets and liabilities; and Level 3—Unobservable inputs that are supported by little or no market activity that are significant to the fair value of assets or liabilities. In connection with the CPM Acquisition, the Company recorded a $19,244,543 liability related to the Earn-Out portion of the purchase consideration. See Note 3, Acquisition, for further discussion of the Earn-Out liability. The Company has classified the Earn-Out liability as a Level 3 liability and the fair value of the Earn-Out liability will be evaluated each reporting period and changes in its fair value will be included in the Company’s results of operations. The fair value of the Earn-Out liability was calculated using a discount rate, approximating the pre-tax cost of debt and corroborated by Monte Carlo simulation, which was then applied to estimated Earn-Out payments. To determine the fair value of the Earn-Out liability, the Company’s management evaluates assumptions that require significant judgment. Changes in certain inputs to the valuation model, including the Company’s management’s estimate of future revenues, can have a significant impact on the estimated fair value. The fair value recorded for the Earn-Out liability may vary significantly from period to period. This variability may result in the actual liability for a period either above or below the estimates recorded in the Company’s consolidated financial statements, resulting in adjustments to the Earn-Out liability with a corresponding non-cash gain or loss recorded to additional paid-in capital. The estimated fair value of certain financial instruments, including cash and cash equivalents, accounts receivable, accounts payable and accrued expenses are carried at historical cost basis, which approximates their fair values because of the short-term nature of these instruments. The recorded value of notes payable approximates their fair value based upon their effective interest rates. Cash and Cash Equivalents The Company considers highly liquid investments with maturities of three months or less at the time of purchase to be cash equivalents. There were no cash equivalents at December 31, 2017 and 2016. The Company’s cash is concentrated in large financial institutions that at times may exceed federally insured limits of $250,000 per financial institution. The Company has not experienced any losses from inception through December 31, 2017. As of December 31, 2017, and 2016, there were deposits of $537,388 and $421,636 , respectively, Accounts Receivable and Allowances Accounts receivables are non-interest bearing and are stated at gross invoice amounts less an allowance for doubtful accounts receivable and an allowance for contractual pricing. Credit is extended to customers based on an evaluation of their financial condition and other factors. The Company generally does not require collateral or other security to support accounts receivable. The Company performs ongoing credit evaluations of its customers and maintains an allowance for potential bad debts. The Company estimates its allowance for doubtful accounts by evaluating specific accounts where information indicates the customers may have an inability to meet financial obligations, such as bankruptcy proceedings and receivable amounts outstanding for an extended period beyond contractual terms. In these cases, the Company uses assumptions and judgment, based on the best available facts and circumstances, to record a specific allowance for those customers against amounts due to reduce the receivable to the amount expected to be collected. These specific allowances are re-evaluated and adjusted as additional information is received. The amounts calculated are analyzed to determine the total amount of the allowance. The Company may also record a general allowance as necessary. The Company’s management estimates its allowance for contractual pricing, by evaluating specific accounts where information indicates the customer is offered contractual pricing and discount allowances. In these arrangements, the Company’s management uses assumptions and judgement, based on the best available facts and circumstances to record a specific allowance for the amounts due from those customers. The allowance is offset by a corresponding reduction to revenue. These specific allowances are re-evaluated and adjusted as additional information is received. The amounts calculated are analyzed to determine the total amount of the allowance. The Company may also record a general allowance as necessary. Accounts deemed uncollectible are written-off in the period when the Company has exhausted its efforts to collect overdue and unpaid receivables or otherwise has evaluated other circumstances that indicate that the Company should abandon such efforts. Previously written-off accounts receivable subsequently collected are recognized as a reduction of bad debt expense when funds are received. Inventories Inventories are stated at the net realizable value (first-in, first-out). Inventories consist entirely of finished goods and include Orthopedic Implants and Biologics. The Company reviews the market value of inventories whenever events and circumstances indicate that the carrying value of inventories may not be recoverable from the estimated future sales price less cost of disposal and normal gross profit. In cases where the market values are less than the carrying value, a write-down is recognized equal to an amount by which the carrying value exceeds the market value of inventories. Property and Equipment Property and equipment are recorded at cost less accumulated depreciation and amortization. Depreciation and amortization are computed using the straight-line method over the estimated useful lives of the related assets per the following table. Leasehold improvements are amortized over the lesser of their useful life or the lease term. Expenditures for additions and improvements are capitalized while repairs and maintenance are expensed as incurred. Category Amortization Period Computer equipment 3 years Furniture and fixtures 3 years Office equipment 3 years Software 3 years Upon the retirement or disposition of property and equipment, the related cost and accumulated depreciation and amortization are removed and a gain or loss is recorded in the consolidated statements of operations. Long-Lived Assets The Company assesses potential impairment to its long-lived assets when there is evidence that events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Events and circumstances considered by the Company in determining whether the carrying value of identifiable intangible assets and other long-lived assets may not be recoverable include, but are not limited to: (i) significant changes in performance relative to expected operating results, (ii) significant changes in the use of the assets, (iii) significant negative industry or economic trends, (iv) a significant decline in the Company’s stock price for a sustained period of time, and (v) changes in the Company’s business strategy. An impairment loss is recorded when the carrying amount of the long-lived asset is not recoverable and exceeds its fair value. The carrying amount of a long-lived asset is not recoverable if it exceeds the sum of the undiscounted cash flows expected to result from the use and eventual disposition of the asset. Any required impairment loss is measured as the amount by which the carrying amount of a long-lived asset exceeds fair value and is recorded as a reduction in the carrying value of the related asset and an expense to operating results. Based upon the Company’s assessment, there were no indicators of impairment of its long-lived assets at December 31, 2017 and 2016. Goodwill Goodwill is the excess of the purchase price over the fair value of net assets of acquired businesses. Goodwill is tested for impairment annually or whenever an event occurs or circumstances change that would indicate that the carrying amount may be impaired. The test for impairment requires us to make several estimates about fair value, most of which are based on projected future cash flows. The Company’s management estimates associated with the goodwill impairment test are considered critical due to the amount of goodwill recorded on our consolidated balance sheets and the judgment required in determining fair value, including projected future cash flows. No goodwill impairment has been recognized during 2017 or 2016. Revenue Recognition The Company recognizes revenue when: (i) persuasive evidence of an arrangement exists; (ii) the fees are fixed or determinable; (iii) no significant Company obligations remain; and (iv) collection of the related receivable is reasonably assured. The Company reports revenues for transactions in which it is the primary obligor on a gross basis and revenues in which it acts as an agent (earning a fixed percentage of the sale) on a net basis, (net of related costs). The Company reports funds collected from customers as deferred revenues until all revenue recognition criteria have been met. Revenues are sales of Orthopedic Implants and Biologics to support orthopedic surgeries and wound care . For customers that purchase products as needed, Products that have been sold are not subject to returns unless the product is deemed defective. Credits or refunds are recognized when they are determinable and estimable. Net revenues have been reduced to account for sales returns, discounts and other incentives. Cost of Revenues Cost of revenues consists of cost of goods sold, freight and shipping costs for items sold to customers, cost of storage, and related supply chain costs. Shipping and Handling Fees The Company includes shipping and handling fees billed to customers in revenues and the related costs in cost of revenues. Income Taxes As a result of the CPM Acquisition, Fuse became the sole managing member of CPM and as a result, began consolidating the financial results of CPM. CPM is treated as a partnership for U.S. federal and most applicable state and local income tax purposes. As a partnership, CPM is not subject to U.S. federal and most applicable state and local income tax purposes. As a partnership, CPM is not subject to U.S. federal and certain state and local income taxes. Any taxable income or loss generated by CPM is passed through to an included in the taxable income or loss of its members. The Company uses the asset and liability method to compute the differences between the tax basis of assets and liabilities and the related financial amounts. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount that more likely than not will be realized. The Company has deferred tax assets and liabilities that reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Deferred tax assets are subject to periodic recoverability assessments. Realization of the deferred tax assets, net of deferred tax liabilities, is principally dependent upon achievement of projected future taxable income. The Company records a liability for uncertain tax positions when it is probable that a loss has been incurred and the amount can be reasonably estimated. As of December 31, 2017, the Company had no liabilities for uncertain tax positions. The Company's policy is to recognize interest and penalties related to income tax matters as a component of income tax expense. The Company continually evaluates expiring statutes of limitations, audits, proposed settlements, changes in tax law, and new authoritative rulings. Segment Information The Company operates in one reportable segment including medical products and supplies. The Company's chief operating decision maker, is its Chief Executive Officer. The Company’s Chief Executive Officer manages the Company's operations as a whole, and does not evaluate revenue, expense or operating income information on any component level. Stock-Based Compensation Stock-based compensation expense is measured at the grant date fair value of the award and is expensed over the requisite service period. For employee stock-based awards, the Company calculates the fair value of the award on the date of grant using the Black-Scholes option pricing model. Determining the fair value of stock-based awards at the grant date under this model requires judgment, including estimating volatility, employee stock option exercise behaviors and forfeiture rates. The assumptions used in calculating the fair value of stock-based awards represent the Company's best estimates, but these estimates involve inherent uncertainties and the application of management judgment. For non-employee stock-based awards, the Company calculates the fair value of the award on the date of grant in the same manner as employee awards, however, the awards are revalued at the end of each reporting period and the prorata compensation expense is adjusted accordingly until such time the non-employee award is fully vested, at which time the total compensation recognized to date shall equal the fair value of the stock-based award as calculated on the measurement date, which is the date at which the award recipient’s performance is complete. The estimation of stock-based awards that will ultimately vest requires judgment, and to the extent actual results or updated estimates differ from original estimates, such amounts are recorded as a cumulative adjustment in the period estimates are revised. Recent Accounting Pronouncements In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2014-09, “Revenue from Contracts with Customers”. ASU 2014-09 is a comprehensive revenue recognition standard that will supersede nearly all existing revenue recognition guidance under current GAAP and replace it with a principle-based approach for determining revenue recognition. ASU 2014-09 will require that companies recognize revenue based on the value of transferred goods or services as they occur in the contract. The ASU also will require additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments and assets recognized from costs incurred to obtain or fulfill a contract. ASU 2014-09 is effective for interim and annual periods beginning after December 15, 2017. Early adoption is permitted only in annual reporting periods beginning after December 15, 2016, including interim periods therein. Entities will be able to transition to the standard either retrospectively or as a cumulative-effect adjustment as of the date of adoption. The Company’s management is in the process of evaluating the impact of ASU 2014-09 on the Company's financial statements and disclosures. In July 2015, the FASB issued ASU No. 2015-11 — “Inventory (Topic 330)”, which requires an entity to measure inventory at the lower of cost and net realizable value. Net realizable value is the estimated selling price in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. The Company adopted ASU 2015-11 as of January 1, 2017 and did not have a material impact on the Company’s financial statements. In February 2016, the FASB issued Accounting Standards Update No. 2016-02, “Leases”, which requires a lessee to record a right of use asset and a corresponding lease liability on the balance sheet for all leases with terms longer than 12 months. ASU 2016-02 is effective for all interim and annual reporting periods beginning after December 15, 2018. Early adoption is permitted. A modified retrospective transition approach is required for lessees for capital and operating leases existing at, or entered after, the beginning of the earliest comparative period presented in the financial statements, with certain practical expedients available. The Company’s management is in the process of evaluating the impact of the adoption of ASU 2016-02 on the Company's financial statements and disclosures. In August 2016, the FASB issued ASU No. 2016-15, “Statement of Cash Flows (Topic 230) Classification of Certain Cash Receipts and Cash payments.” The update addresses eight specific cash flow issues with the objective of reducing the existing diversity in practice. This ASU is effective for the public business entities for fiscal years beginning after December 15, 2017 and for interim periods within those fiscal years. The amendments in this update may be applied retrospectively or prospectively and early adoption is permitted. The Company’s management In November 2016, the FASB issued ASU Update No. 2016-18 — “Statement of Cash Flows (Topic 230): Restricted Cash (A Consensus of the FASB EITF)”. ASU 2016-18 requires that a statement of cash flows explain the change during the period in the total of cash, cash equivalents, and amounts generally described as restricted cash or restricted cash equivalents. These amounts should be included with cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts shown on the statement of cash flows. This amendment does not provide a definition of restricted cash or restricted cash equivalents. The update will be effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2017. The Company’s management is in the process of evaluating the impact of ASU 2016-18 on the Company’s financial statements and disclosures. Other recent accounting pronouncements issued by the FASB, including its Emerging Issues Task Force, the American Institute of Certified Public Accountants, and the Securities and Exchange Commission, (the “SEC”) did not or are not believed by management to have a material impact on the Company's present or future consolidated financial statements.

Acquisition

Acquisition	12 Months Ended
	Dec. 31, 2017
Business Combinations [Abstract]
Acquisition	Note 3. Acquisition Between the period July 2016 through October 2016, the Company obtained three loans in the aggregate amount of $150,000 in exchange for the Notes bearing 10% interest per annum, with principal due and payable, upon demand of the payee. The Notes were issued as follows: $100,000 to NC 143, and $50,000 to RMI. The Investors have the sole discretion and right to convert all or any portion of the then unpaid principal and interest balance of the Notes into shares of the Company’s common stock at a conversion price of $0.08 per share. (see note 6). On December 19, 2016, the Company entered into a Stock Purchase Agreement by and between the Investors and the Company, pursuant to which NC 143 acquired 5 million shares of the Company’s common stock for a purchase price of $400,000 and RMI acquired 4 million shares of the Company’s common stock for a purchase price of $320,000 effective as of the Change-in-Control Date. Direct offering costs of the Company were $64,609 in connection with the offer and sale of the Investor Shares, and, net proceeds from the offer and sale of the Investor Shares were $655,391. The closing of the Stock Purchase Agreement resulted in a change-in-control of the Company whereby the Investors beneficially acquired approximately 61.4% of the Company’s common stock issued and outstanding immediately after the Change-in-Control Date. Mark W. Brooks became our Chairman of the Board and Christopher C. Reeg became our Chief Executive Officer, as described in our Current Report on Form 8-K, filed with the Commission on December 23, 2016, which is herein incorporated by reference. Fuse recorded a goodwill asset of $820,000 to reflect the excess of the carrying value of the Company’s net assets over their fair value as implied by the purchase price paid by the Investors on the Change-in-Control Date. On December 15, 2017, Fuse entered into the CPM Acquisition Agreement with NC 143 pursuant to which Fuse would purchase all of the outstanding membership interests of CPM. On December 29, 2017, Fuse completed the previously-announced CPM Acquisition, pursuant to the CPM Acquisition Agreement by Fuse and NC 143, dated December 15, 2017, whereby Fuse would purchase all of the outstanding membership interests of CPM. Fuse issued 50 million shares of its common stock, par value $0.01 per share in exchange for 100% of the outstanding membership interests of CPM, at an agreed-upon value of $0.20 per share of common stock. The effective date of the CPM Acquisition was December 31, 2017. Additional one-time costs incurred with the acquisition totaled approximately $200,000 and are included in the selling, general, administrative and other expenses on the consolidated statements of operations. The CPM Acquisition Agreement provides for Earn-Out payments to NC 143 subject to certain sales and profitability targets being met by the Company for years after 2017. The fair value of the Earn-Out was recorded at $19,244,543 as of the Effective Date. The Company recorded the Earn-Out at its fair value of the Effective Date. The CPM Acquisition Agreement provides for a working capital post-closing adjustment (“Post-Closing Adjustment”) for certain changes in CPMs current assets and current liabilities pursuant to the CPM Acquisition Agreement. The Post-Closing Adjustment is approximately $397,463 and will be paid in shares of the Company’s common stock within 120 days the Effective Date. On the Effective Date of the closing of the CPM acquisition, NC 143 and RMI beneficially acquired approximately 90.4% of the Company’s common stock outstanding. Fuse is the legal acquirer and, for accounting purposes, CPM was deemed to have acquired the Company in the CPM Acquisition. CPM is the successor entity and becomes the reporting entity which combines Fuse at the Change-in-Control Date, with the assets and liabilities of both companies combined at historical cost. (see note 1). The following unaudited pro forma summary financial information presents the consolidated results of operations for the Company as if the CPM Acquisition had occurred on January1, 2016. The pro forma results are shown for illustrative purposes only and do not purport to be indicative of the results that would have been reported if the CPM Acquisition had occurred on the date indicated or indicative of the results that may occur in the future. Unaudited pro forma information for the twelve months ended December 31, 2016 is as follows: Year Ended December 31, 2016 - Unaudited Historical Fuse Medical, Inc. Historical CPM Medical Consultants, LLC Pro forma Adjustments Pro forma Combined Revenue $ 567,607 $ 25,647,353 $ (103,578 ) $ 26,111,382 Net (loss) income $ (585,935 ) $ 3,035,296 $ - $ 2,449,361 Net (loss) income per common share - basic $ - $ - $ - $ 0.34 The supplemental pro forma earnings were adjusted to exclude $103,578 for the year ended December 31, 2016. The number of shares outstanding used in calculating the net (loss) per common share – basic was 7,185,890 for the year ended December 31, 2016. The Company is managed and operates in one segment, with Fuse merged into the CPM existing operations.

Property and Equipment

Property and Equipment	12 Months Ended
	Dec. 31, 2017
Property Plant And Equipment [Abstract]
Property and Equipment	Note 4. Property and Equipment Property and equipment consisted of the following at December 31, 2017 and 2016: December 31, 2017 December 31, 2016 Computer equipment $ - $ 29,290 Furniture and fixtures 5,047 6,347 Leasehold improvements - 6,728 Office equipment 21,913 9,221 Software - 34,252 26,960 85,838 Less: accumulated depreciation (10,065 ) (71,091 ) Property and equipment, net $ 16,895 $ 14,747 During the year ended December 31, 2017, the Company sold fixed assets having a net book value of $607 for cash proceeds of $300, retired fixed assets no longer in use with a net book value of $3,058, and recorded $8,732 of insurance settlements proceeds for a fully depreciated fixed asset. Depreciation expense for the years ended December 31, 2017 and 2016 was $14,521 and $19,091, respectively.

Revolving Line of Credit

Revolving Line of Credit	12 Months Ended
	Dec. 31, 2017
Debt Disclosure [Abstract]
Revolving Line of Credit	Note 5. Revolving Line of Credit On December 29, 2017, Fuse became party to a revolving line of credit (“RLOC”) with ZB, N.A. (d/b/a Amegy Bank), to facilitate the December 31, 2017 CPM Acquisition. The RLOC establishes an asset based senior secured revolving credit facility in the amount of $5,000,000. The RLOC bears interest at a variable rate based on the one-month LIBOR rate plus 3.00% (effective rate of 4.56% at December 31, 2017). The RLOC contains customary representation, warranties, covenants, events of default, and is collateralized by substantially all of the Company’s assets. The Chairman of the Board personally guarantees fifty percent (50%) of the outstanding loan amount. The outstanding balance of the RLOC was $3,415,351 and $3,305,347 at December 31, 2017 and 2016, respectively. Interest expense incurred was $134,668 and $133,334 for 2017 and 2016, respectively.

Notes Payable - Related Parties

Notes Payable - Related Parties	12 Months Ended
	Dec. 31, 2017
Debt Disclosure [Abstract]
Notes Payable - Related Parties	Note 6. Notes Payable – Related Parties During July 2016 through October 2016, the Company obtained three short-term loans in the aggregate amount of $150,000 in exchange for promissory notes bearing 10% interest per annum, which principal shall be due and payable, upon demand of the payee. Notwithstanding, at the holder’s sole discretion, the holder has the right to convert all or any portion of the then unpaid principal and interest balance into shares of the Company’s common stock at a conversion price of $0.08 per share. On each respective date of issuance, the conversion price of each of the promissory notes was less than the market price of the Company’s common stock. This resulted in a beneficial conversion feature in the aggregate amount of $117,500, which was treated as a discount to each of the promissory notes and amortized over the term of each respective promissory note. Subsequent to the issuance of the notes, affiliates of the noteholders entered into the Stock Purchase Agreement with the Company (See Notes 1 and 11). Notes payable – related parties consisted of the following: December 31, 2017 December 31, 2016 Notes Payable originating July 15, 2016; no monthly payments required; bearing interest at 10%; due on December 31, 2016, convertible on demand $ 50,000 $ 50,000 Notes Payable originating August 23, 2016; no monthly payments required; bearing interest at 10%; due on December 31, 2016, convertible on demand 50,000 50,000 Notes Payable originating October 19, 2016; no monthly payments required; bearing interest at 10%; due on December 31, 2016, convertible on demand 50,000 50,000 Total 150,000 150,000 Less: current maturities (150,000 ) (150,000 ) Amount due after one year $ - $ - During the year ended December 31, 2017 and 2016, interest expense of $27,000 and $13,587 (of which $13,094 was related to the amortization of the beneficial conversion feature), respectively, was recognized on outstanding notes payable – related parties. As of December 31, 2017, and 2016, accrued interest payable was $32,096 and $5,096, respectively, which is included in accrued expenses on the accompanying consolidated balance sheets.

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2017
Commitments And Contingencies Disclosure [Abstract]
Commitments and Contingencies	Note 7. Commitments and Contingencies Legal Matters On January 27, 2014, M. Richard Cutler and Cutler Law Group, P.C. (the “Plaintiffs”) filed a complaint in the District Court of Harris County, Texas, 201 On September 18, 2015, Plaintiffs refiled a complaint in the District Court of Harris County, Texas, Cause No. 2015-55652 and added PH Squared, LLC as an additional Plaintiff. Thereafter, the term “Plaintiffs” collectively refers to M. Richard Cutler, Cutler Law Group, P.C. and PH Squared, LLC. The new complaint asserts essentially the same claims as the original nonsuited complaint: (i) suit on sworn account against Fuse; (ii) fraud against all Defendants; and (iii) breach of contract against all Defendants for allegedly violating a non-circumvention/non-disclosure agreement. Richard Cutler is the sole principal of Cutler Law Group, P.C., which provided legal representation to its clients, Craig Longhurst and PH Squared, LLC d/b/a PharmHouse Pharmacy (“Cutler’s Client”), during a failed merger attempt between Fuse and Golf Rounds.com, Inc. (the “Failed Transaction”). The Plaintiffs have alleged that the Failed Transaction failed to materialize notwithstanding the efforts of Mr. Cutler, his law firm and PH Squared, LLC. The Plaintiffs have further alleged that the Defendants continued to pursue a similar transaction without Cutler’s Client or the Plaintiffs. The Plaintiffs claim that the Defendants are responsible for damages in the amount of $46,465 plus interest for the breach of contract claim because Plaintiffs were not paid their legal fees by Cutler’s Client and Plaintiffs did not receive equity in the merged company that would have resulted from the Failed Transaction. Plaintiffs are also asking for undisclosed damages related to the fraud and breach of contract claims, and are asking for exemplary damages as a result of allegedly intentional fraud that some or all of the Defendants allegedly committed. Plaintiffs also seek their attorneys’ fees and costs for having brought the action. On November 18, 2015, Fuse filed a counterclaim against PH Squared, LLC for breach of contract and further asserted a counterclaim and third-party claim against PH Squared, LLC’s principle, Craig Longhurst, for fraud in the inducement. Fuse also seeks a declaratory judgment on the intended third-party beneficiary status of Plaintiffs Cutler and Cutler Law Group related to a non-circumvention/non-disclosure agreement. The trial date for the above matter was scheduled for May 1, 2017, but it was moved to July 24, 2017 in order to allow for some additional discovery. During April 2017, one of the named individuals in the complaint filed for bankruptcy protection. There is currently no trial date set. The Company’s management continues to believe that the lawsuit is completely without merit and will vigorously contest it and protect the Company’s interests. Operating Leases The Company leases office space under a noncancelable operating lease agreement, from a real estate investments company that is owned and controlled by the Company’s Chairman of the Board and President. This lease terminated December 31, 2017 with month-to-month renewals. The lease requires monthly payments of $14,000. Annual rent expense was approximately $142,000 and $120,000 for the years ended December 31, 2017 and 2016, and are included in selling, general, administrative and other expenses. The Company leases office equipment under two noncancelable operating lease agreements which expire March 2019 and February 2021. In aggregate, these office equipment leases require monthly payments of approximately $779. Rent expense for the equipment leases totaled approximately $11,000 and $8,000 for the years ended December 31, 2017 and 2016, respectively, and are included in selling, general, administrative and other expenses. The following is a schedule by years of future minimum rental payments required under operating leases that have initial or remaining noncancelable lease terms in excess of one year as of December 31, 2017: Year ending December 31, 2018 $ 9,000 2019 5,000 2020 3,000 2021 500 $ 17,500

Stockholders' Equity

Stockholders' Equity	12 Months Ended
	Dec. 31, 2017
Stockholders Equity Deficit [Abstract]
Stockholders' Equity	Note 8. Stockholders’ Equity Authorized Capital The Company has authorized 100,000,000 shares of common stock having a par value of $0.01 per share, and its Board is authorized to issue shares of the common stock, in one or more series, and to fix for each such series the voting powers, designations, preferences, or other special rights and the qualifications, limitations or restrictions. The Company has authorized 20,000,000 shares of preferred stock having a par value of $0.01 per share, and its Board is authorized to issue shares of the preferred stock, in one or more series, and to fix for each such series the voting powers, designations, preferences, or other special rights and the qualifications, limitations or restrictions. Common Stock On December 29, 2017, Fuse completed the previously-announced acquisition of CPM, pursuant to the CPM Acquisition Agreement by Fuse and NC 143, dated December 15, 2017, whereby the Fuse would purchase all of the outstanding membership interests of CPM. Fuse issued 50,000,000 shares of its common stock, par value $0.01 per share in exchange for 100% of the outstanding equity interests of CPM, at an agreed-upon value of $0.20 per share of common stock, as reflected in the fairness opinion provided by ValueScope. The Effective Date of the CPM acquisition was December 31, 2017. On December 19, 2016, the Company entered into the Stock Purchase Agreement by and between the Investors and the Company, pursuant to which NC 143 acquired , effective as of the Change-in-Control Date. Direct offering costs of the Company were $64,609 in connection with the offer and sale of the Investor Shares, and, net proceeds from the sale of the Investor Shares were $655,391. Stock Incentive Plans The Company has a stock-based compensation plan which provides for the granting of equity awards, including qualified incentive and non-qualified stock options, stock appreciation awards and restricted stock awards to employees, directors, consultants and advisors; the 2017 Equity Incentive Plan (the “2017 Plan”), which was adopted by the Company’s Board on April 5, 2017. The awards are subject to a vesting schedule as set forth in individual agreements. On September 21, 2017, the Board approved an amendment to the 2017 Plan to increase the number of shares of common stock authorized for issuance under the 2017 Plan from 1,500,000 shares of common stock to 2,500,000 shares of common stock. On October 4, 2017, the Board approved an amendment to the 2017 Plan to increase the number of shares of common stock authorized for issuance under the 2017 Plan from 2,500,000 shares of common stock to 4,500,000 shares of common stock. Stock Options The Company estimates the fair value of share-based compensation utilizing the Black-Scholes option pricing model, which is dependent upon several variables such as the expected option term, expected volatility of the Company’s stock price over the expected option term, expected risk-free interest rate over the expected option term, expected dividend yield rate over the expected option term, and an estimate of expected forfeiture rates. The Company believes this valuation methodology is appropriate for estimating the fair value of stock options granted to employees and directors which are subject to ASC Topic 718 requirements. These amounts are the Company’s estimates and thus may not be reflective of actual future results, nor amounts ultimately realized by recipients of these grants. The Company recognizes compensation on a straight-line basis over the requisite service period for each award. The Company did not grant stock options in 2017. The following table summarizes the assumptions the Company utilized to record compensation expense for stock options granted to employees during the year ended December 31, 2016: Assumptions For the Year Ended December 31, 2017 For the Year Ended December 31, 2016 Expected term (years) - 2.5 Expected volatility 0 % 162 % Weighted-average volatility 0 % 162 % Risk-free interest rate 0.00 % 1.43 % Dividend yield 0.0 % 0.0 % Expected forfeiture rate n/a n/a The Company’s management utilized the simplified method to estimate the expected life for stock options granted to employees, as the Company does not have sufficient historical data regarding stock option exercises. The expected volatility is based on historical volatility of the Company’s common stock subsequent to the closing of the Reverse Merger. The risk-free interest rate is based on the U.S. Treasury yields with terms equivalent to the expected life of the related option at the time of the grant. Dividend yield is based on historical trends. While the Company’s management believes these estimates are reasonable, the compensation expense recorded would increase if the expected life was increased, a higher expected volatility was used, or if the expected dividend yield increased. A summary of the Company’s stock option activity during the year ended December 31, 2017 is presented below: No. of Shares Weighted Average Exercise Price Weighted Average Remaining Contractual Term Aggregate Intrinsic Value Balance outstanding at December 31, 2016 1,304,788 $ 0.22 Granted - $ - Exercised — $ - Forfeited — $ - Expired (2,736 ) $ 12.13 Balance outstanding at December 31, 2017 1,302,052 $ 0.20 3.3 $ 1,717,000 Exercisable at December 31, 2017 1,302,052 $ 0.20 3.3 $ 1,717,000 The weighted-average grant-date fair value of options granted during the year ended December 31, 2016 was $0.09. Restricted Common Stock On September 21, 2017, the Company’s Board granted an aggregate of 325,000 Restricted Stock Awards (“RSA’s”) pursuant to the Company’s 2017 Plan, to the Board as annual compensation. The RSA’s have a fair market value of $0.78 on the date of grant and fully vest upon the one-year anniversary of the date of grant or September 21, 2018. As of December 31, 2017, the Company had amortized $21,664 relating to the vesting of these shares which is included in selling, general, and administrative expenses, and $43,336 which will be recognized as an expense in future periods as the shares vest. On September 21, 2017, the Company’s Board granted an aggregate of 2,000,000 RSA’s pursuant to the 2017 Plan, to the Company’s independent directors as compensation. The RSA’s have a fair market value of $0.78 on the date of grant and vest fully upon the earlier of a change in control of the Company or the Company’s listing on a national securities exchange. As of December 31, 2017, the Company had not amortized any amounts relating to the vesting of these shares due to the uncertainty of meeting these vesting milestones. On December 14, 2017, the Board awarded a total of 942,500 shares of common stock of the Company, in the form of RSAs issued in accordance with the 2017 Plan of the Company, to the members of the Board of the Company as annual compensation for services rendered to the Company as Board members. Each member of the Board was granted an RSA constituting 188,500 shares of the Company’s common stock. Based in part on the analysis of the fairness opinion provided by a third-party valuation specialist, the Board determined that the common stock within each RSA had a fair market value of $0.20 on the date of grant. As of December 31, 2017, the Company had amortized $20,945 relating to the vesting of these shares which is included in selling, general, administrative and other expenses, and $167,555 which will be recognized as an expense in future periods as the shares vest. The Board voted to revise the $0.78 fair market value for each share issued pursuant to each RSA granted on September 21, 2017, to $0.20. The Board voted to amend the indicated fair market value in the September grants to $0.20 based in part on the analysis within the fairness opinion provided by the third-party valuation specialist. The following table summarizes restricted common stock activity: Number of Shares Fair Value Weighted Average Grant Date Fair Value Non-vested, December 31, 2016 - $ - $ - Granted 3,267,500 1,813,500 0.56 Vested - - - Forfeited - - - Non-vested, December 31, 2017 3,267,500 $ 1,813,500 $ 0.56

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2017
Income Tax Disclosure [Abstract]
Income Taxes	Note 9. Income Taxes As a result of the CPM Acquisition, Fuse became the sole managing member of CPM and as a result, began consolidating the financial results of CPM. CPM is treated as a partnership for U.S. federal and most applicable state and local income tax purposes. As a partnership, CPM is not subject to U.S. federal and most applicable state and local income tax purposes. As a partnership, CPM is not subject to U.S. federal and certain state and local income taxes. Any taxable income or loss generated by CPM is passed through to an included in the taxable income or loss of its members. Fuse is subject to U.S. federal income taxes, in addition to state and local income taxes. The components of income tax expense (benefit) are as follows: For the Year Ended December 31, 2017 For the Year Ended December 31, 2016 Current: Federal $ - $ - State 40,818 51,627 40,818 51,627 Deferred: Federal - - State - - - - Total Income tax expense (benefit) $ 40,818 $ 51,627 Significant components of the Company's deferred income tax assets and liabilities are as follows: December 31, 2017 December 31, 2016 Deferred tax assets: Net operating loss carryover $ 172,704 $ 224,381 Intangibles 40,342 - Accounts receivable 81,927 - Compensation 57,458 80,850 Inventory 25,792 - Total deferred tax assets 378,223 305,231 Deferred tax liabilities: Prepaid expenses - - Property and equipment (2,945 ) 2,795 Total deferred tax liabilities (2,945 ) 2,795 Deferred tax assets, net 375,278 308,026 Valuation allowance: Beginning of year (308,026 ) (700,713 ) (Increase) decrease during year 308,026 392,687 Ending balance - (308,026 ) Net deferred tax asset $ 375,278 $ - In 2016 and 2017 CPM is treated as a partnership for U.S. federal and most applicable state and local income tax purposes. As a partnership, CPM is not subject to U.S. federal and certain state income taxes. Any taxable income or loss generated by CPM during 2016 and 2017 is passed through to and included in the taxable income or loss of its members. Accordingly, our consolidated financial statements for 2017 do not include a provision for federal or state income tax purposes. Fuse is treated as a corporation for U.S. federal and applicable state and local income tax purposes. As a corporation, Fuse is subject to U.S. federal and applicable state income taxes. A valuation allowance is established if it is more likely than not that all or a portion of the deferred tax asset will not be realized. The Company has recorded a valuation allowance in 2016 due to the uncertainty of realization. As a result of the organizational transactions of Fuse and CPM in 2017, it is more likely than not that the tax deferred tax assets benefits would be realized. At December 31, 2017, Fuse had $ 822,399 These carry forward benefits may be subject to annual limitations due to the ownership change limitations imposed by the Internal Revenue Code and similar state provisions. The annual limitation, if imposed, may result in the expiration of net operating losses before utilization. A reconciliation of income tax computed at the U.S. statutory rate to the effective income tax rate is as follows: For the Year Ended December 31, 2017 For the Year Ended December 31, 2016 Statutory U.S. federal income tax rate 35.0 % 35.0 % State income taxes, net of federal tax benefit 5.8 % 1.7 % Permanent differences 3.8 % 0.3 % Other reconciling items 20.5 % 19.8 % LLC flow-through structure (59.3 %) (42.1 %) Valuation allowance 0.0 % (13.0 %) Effective income tax rate 5.8 % 1.7 %

Concentrations

Concentrations	12 Months Ended
	Dec. 31, 2017
Nature Of Operations And Going Concern [Abstract]
Concentrations	Note 10. Concentrations Concentration of Revenues, Accounts Receivable and Suppliers For the years ended December 31, 2017 and 2016, the following significant customers had an individual percentage of total revenues equaling 10% or greater: For the Year Ended December 31, 2017 For the Year Ended December 31, 2016 Customer 1 (related party) 18.70 % 18.33 % Customer 2 18.06 % 11.61 % Totals 36.76 % 29.94 % At December 31, 2017 and 2016, the following significant customers had a concentration of accounts receivable representing 10% or greater of accounts receivable: December 31, 2017 December 31, 2016 Customer 1 (related party) 24.80 % 25.21 % Customer 2 15.26 % 12.92 % Totals 40.06 % 38.13 % For the years ended December 31, 2017 and 2016, the following significant suppliers represented 10% or greater of goods purchased: For the Year Ended December 31, 2017 For the Year Ended December 31, 2016 Supplier 1 22.34 % 22.36 % Totals 22.34 % 22.36 %

Related Party Transactions

Related Party Transactions	12 Months Ended
	Dec. 31, 2017
Related Party Transactions [Abstract]
Related Party Transactions	Note 11. Related Party Transactions Change in Control Between the period July 2016 through October 2016, we obtained three loans in the aggregate amount of $150,000 in exchange for convertible promissory notes (the “Notes”) bearing 10% interest per annum, with principal due and payable, upon demand of the payee. The Notes were issued as follows: $100,000 to NC 143 Family Holdings, LP, a family limited partnership controlled by Mark W. Brooks (“NC 143”), our Chairman of the Board of Directors (the “Board”); and $50,000 to Reeg Medical Industries, Inc., an investment holding company owned and controlled by Christopher C. Reeg, our Chief Executive Officer (“RMI”, and together with NC 143, the “Investors”). The Investors have the sole discretion and right to convert all or any portion of the then unpaid principal and interest balance of the Notes into shares of our common stock at a conversion price of $0.08 per share. Since December of 2016, the Company has been controlled by the Investors, who are its two primary stockholders. On the Change- in-Control Date the Company entered into the Stock Purchase Agreement by and between the Investors and the Company, pursuant to which the Investors received the Investor Shares, effective as of the Change-in-Control Date. For more details please see “Item 1. Business” of this 2017 Annual Report The closing of the Stock Purchase Agreement resulted in a change-in-control of the Company whereby the Investors beneficially acquired approximately 61.4% of the Company’s Common Stock issued and outstanding immediately after the Change-in-Control Date. Mark W. Brooks became the Chairman of the Board and Christopher C. Reeg became our Chief Executive officer, as described in our Current Report on Form 8-K, filed with the SEC on December 23, 2016, which is herein incorporated by reference. CPM Acquisition On December 15, 2017, Fuse entered into an agreement with NC 143 pursuant to which Fuse would purchase all of the outstanding membership interests of CPM Medical Consultants, LLC (“CPM”) (the “CPM Acquisition Agreement” and such transaction, the “CPM Acquisition”). On December 29, 2017, Fuse completed the previously-announced acquisition of CPM Acquisition, pursuant to the CPM Acquisition Agreement by Fuse and NC 143, dated December 15, 2017, whereby Fuse would purchase all of the outstanding membership interests of CPM. Fuse issued 50 million shares of its common stock, par value $0.01 per share in exchange for 100% of the outstanding membership interests of CPM, at an agreed-upon value of $0.20 per share of common stock. The effective date of the CPM Acquisition was December 31, 2017 (the “Effective Date”). The CPM Acquisition provides for contingent payments to NC 143 subject to certain sales and profitability targets being met by the Company for years after 2017. For accounting purposes, CPM was deemed to have acquired Fuse in the CPM Acquisition because NC 143 and RMI had combined majority control of our issued and outstanding common stock and they jointly have the power to appoint a majority of our members of the Board. Because Fuse is the legal acquirer, the CPM Acquisition was accounted for as a reverse acquisition of an entity under common control. CPM is the successor entity and becomes the reporting entity which combines Fuse at the Change-in-Control Date, with the assets and liabilities of both companies combined at historical cost (collectively, Fuse and CPM consolidated or the “Company”). (see note 3) Lease with 1565 North Central Expressway, LP The Company leases an approximately 11,500 square-foot space as its principal executive office, located at 1565 North Central Expressway, Suite 220, Richardson, Texas 75080 from 1565 North Central Expressway, LP, a real estate investment company that is owned and controlled by the Company’s Chairman of the Board and President. The CPM lease was effective January 1, 2013 and the Fuse lease was effective July 14, 2017. The leases terminated December 31, 2017 with month-to-month renewals. The leased property does not have material costs of complying with environmental laws. The Company believes its present business property is adequate and suitable to support its mid-term strategies and initiatives for growth. They are in the process of renegotiating a lease renewal, but there is a large supply of comparable commercial property available in the general area that we would be able to lease at comparable lease rates. AmBio Contract The Company has engaged AmBio Staffing, LLC (“AmBio”) a Texas licensed Professional Employment Organization, (“PEO”) to provide payroll processing, employee benefit administration, and related human capital services effective January 1, 2017. The Company’s Chairman of the Board and President, Mark W. Brooks, owns and controls AmBio. As of March 26, 2018, AmBio operations supports approximately 74 full time equivalents (“FTE”). Of those 74 FTEs, 42 FTEs directly support the Company, 19 FTEs support the operations of other companies and the Company shares 13 FTEs with other companies. Operations The Company enters into various related party transactions with entities that are owned by or affiliated with the Company’s Named Executive Officers and Directors. The transactions included sales, purchases, commissions paid for services, and revenues related to services provided to the related party. MedUSA Group, LLC MedUSA Group, LLC (“MedUSA”) is a sub-distributor owned and controlled by our Chairman of the Board and Chief Executive Officer. During the years ended December 31, 2017 and 2016, we had net sales of approximately $5,054,000 and $4,797,000, respectively, to MedUSA for product used in surgical cases. During the years ended December 31, 2017 and 2016, we incurred commission expense of approximately $962,000 and $642,000, respectively, to MedUSA for services provided to us in surgical cases. As of December 31, 2017, and 2016, we had balances due from MedUSA of approximately $1,684,000 and $1,752,000, respectively, included in accounts receivable on the accompanying consolidated balance sheets. Texas Overlord, LLC Texas Overlord, LLC (“Overlord”) is an investment holding company owned and controlled by our Chairman of the Board. During the years ended December 31, 2017 and 2016, we had net sales of approximately $1,953,000 and $0.00, respectively, to Overlord for product used in surgical cases. During the years ended December 31, 2017 and 2016, we incurred commission expense of approximately $101,000 and $0.00, respectively, to Overlord for services provided to us in surgical cases. As of December 31, 2017, and 2016, we had balances due from Overlord of approximately $444,000 and $0.00, respectively, included in accounts receivable on the accompanying consolidated balance sheets. N.B.M.J., Inc. N.B.M.J., Inc. (“NBMJ”) is a Durable Medical Equipment (“DME”) distributor and a wound care distributor owned and controlled by our Chairman of the Board. During the years ended December 31, 2017 and 2016, we had net sales of approximately $162,000 and $715,000, respectively, to NBMJ for product used in surgical cases. During the years ended December 31, 2017 and 2016, we incurred commission expense of approximately $0.00 and $0.00, respectively, to NBMJ for services provided to us in surgical cases. As of December 31, 2017, and 2016, we had balances due from NBMJ of approximately $0.00 and $47,000, respectively, included in accounts receivable on the accompanying consolidated balance sheets. Palm Springs Partners d/b/a Maxim Surgical, LLC Palm Springs Partners d/b/a Maxim Surgical, LLC (“Maxim”) is a manufacturer/distributor owned and controlled by Christopher C. Reeg, our Chief Executive Officer and Secretary, and Mark W. Brooks, our Chairman of the Board and President. During the year ending December 31, 2017 and 2016, we had net sales of approximately $202,000 and $164,000 to Maxim for product used in surgical cases. During the year ending December 31, 2017 and 2016, we purchased approximately $468,000 and $458,000 from Maxim. As of December 31, 2017, and 2016, we had a balance due from Maxim of approximately $50,000 and $45,000, included in accounts receivable on the accompanying consolidated balance sheets. As of December 31, 2017, and 2016, we had a balance due to Maxim of approximately $93,000 and $102,000, included in accounts payable on the accompanying consolidated balance sheets. Sintu, LLC Sintu, LLC (“Sintu”) is a sub-distributor owned and controlled by Mark W. Brooks, our Chairman of the Board and President. During the year ended December 31, 2017 and 2016, we incurred commission expense of approximately $1,114,000 and $692,000 to Sintu for services provided in surgical cases. Other During the years ended December 31, 2017 and 2016, the Company had net sales of approximately $1,055,000 and $396,000, respectively, to these entities for product used in surgical cases. During the years ended December 31, 2017 and 2016, the Company had purchases of approximately $128,000 and $8,000, respectively, from these entities. During the years ended December 31, 2017 and 2016, the Company incurred commission expense of approximately $248,000 and $702,000, respectively, to these entities for services provided in surgical cases. The Company also had other income related to charges for shared services it provided to the related party of approximately $33,000 and $114,000 for the years ended December 31, 2017 and 2016, respectively, included with selling, general, and administrative expenses on the accompanying consolidated statements of operations. As of December 31, 2017, and 2016, the Company had balances due from these entities of approximately $169,000 and $159,000, respectively, included in accounts receivable on the accompanying consolidated balance sheets. The Company engages AmBio, a licensed PEO to provide payroll processing, employee benefit administration, and related human capital services. AmBio is controlled by the Chairman of the Board and President. As of December 31, 2017, and 2016, the Company had balances due to AmBio of approximately $112,000 and $107,000. As of December 31, 2017, and 2016, approximately $162,000 and $162,000 of fees were paid to AmBio for such services, respectively, and are reflected with in selling, general, and administrative expenses on the accompanying consolidated statements of operations.

Subsequent Events

Subsequent Events	12 Months Ended
	Dec. 31, 2017
Subsequent Events [Abstract]
Subsequent Events	Note 12. Subsequent Events In preparing these financial statements, the Company has evaluated events and transactions for potential recognition or disclosure through April 5, 2018, the date the financial statements were available to be issued.

Significant Accounting Polici19

Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2017
Accounting Policies [Abstract]
Principles of Consolidation	The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary. Intercompany transactions have been eliminated in consolidation.
Use of Estimates	The preparation of the consolidated financial statements in accordance with generally accepted accounting principles in the United State, (“GAAP”). GAAP requires the Company’s management to make estimates and assumptions that affect the reported amounts in the consolidated financial statements. Actual results could differ from those estimates. Significant estimates in the accompanying consolidated financial statements include the allowances for doubtful accounts and contractual pricing, valuation of inventories, accrued commissions, the fair value calculation of stock based compensation, and fair value of Earn-Out liability.
Earnings Per Share	Basic net income per common share is calculated by dividing net income attributable to common stockholders by the weighted-average number of common shares outstanding during the period, without consideration of common stock equivalents. Shares of restricted stock are included in the basic weighted average number of common shares outstanding from the time they vest. Diluted net income per common share is computed by dividing net income attributable to common stockholders by the weighted-average number of common share equivalents outstanding for the period determined using the treasury stock method. As of December 31, 2017, 700,000 outstanding common stock equivalents have been included with diluted net earnings per share. As of December 31, 2017, and 2016, common stock equivalents included options to purchase 1,302,052 and 1,304,788 common shares, respectively.
Fair Value Measurements	Fair value is the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants. The Company classifies assets and liabilities recorded at fair value under the fair value hierarchy based upon the observability of inputs used in valuation techniques. Observable inputs (highest level) reflect market data obtained from independent sources, while unobservable inputs (lowest level) reflect internally developed market assumptions. The fair value measurements are classified under the following hierarchy: Level 1—Observable inputs that reflect quoted market prices (unadjusted) for identical assets and liabilities in active markets; Level 2—Observable inputs, other than quoted market prices, that are either directly or indirectly observable in the marketplace for identical or similar assets and liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets and liabilities; and Level 3—Unobservable inputs that are supported by little or no market activity that are significant to the fair value of assets or liabilities. In connection with the CPM Acquisition, the Company recorded a $19,244,543 liability related to the Earn-Out portion of the purchase consideration. See Note 3, Acquisition, for further discussion of the Earn-Out liability. The Company has classified the Earn-Out liability as a Level 3 liability and the fair value of the Earn-Out liability will be evaluated each reporting period and changes in its fair value will be included in the Company’s results of operations. The fair value of the Earn-Out liability was calculated using a discount rate, approximating the pre-tax cost of debt and corroborated by Monte Carlo simulation, which was then applied to estimated Earn-Out payments. To determine the fair value of the Earn-Out liability, the Company’s management evaluates assumptions that require significant judgment. Changes in certain inputs to the valuation model, including the Company’s management’s estimate of future revenues, can have a significant impact on the estimated fair value. The fair value recorded for the Earn-Out liability may vary significantly from period to period. This variability may result in the actual liability for a period either above or below the estimates recorded in the Company’s consolidated financial statements, resulting in adjustments to the Earn-Out liability with a corresponding non-cash gain or loss recorded to additional paid-in capital. The estimated fair value of certain financial instruments, including cash and cash equivalents, accounts receivable, accounts payable and accrued expenses are carried at historical cost basis, which approximates their fair values because of the short-term nature of these instruments. The recorded value of notes payable approximates their fair value based upon their effective interest rates.
Cash and Cash Equivalents	The Company considers highly liquid investments with maturities of three months or less at the time of purchase to be cash equivalents. There were no cash equivalents at December 31, 2017 and 2016. The Company’s cash is concentrated in large financial institutions that at times may exceed federally insured limits of $250,000 per financial institution. The Company has not experienced any losses from inception through December 31, 2017. As of December 31, 2017, and 2016, there were deposits of $537,388 and $421,636 , respectively,
Accounts Receivable and Allowances	Accounts receivables are non-interest bearing and are stated at gross invoice amounts less an allowance for doubtful accounts receivable and an allowance for contractual pricing. Credit is extended to customers based on an evaluation of their financial condition and other factors. The Company generally does not require collateral or other security to support accounts receivable. The Company performs ongoing credit evaluations of its customers and maintains an allowance for potential bad debts. The Company estimates its allowance for doubtful accounts by evaluating specific accounts where information indicates the customers may have an inability to meet financial obligations, such as bankruptcy proceedings and receivable amounts outstanding for an extended period beyond contractual terms. In these cases, the Company uses assumptions and judgment, based on the best available facts and circumstances, to record a specific allowance for those customers against amounts due to reduce the receivable to the amount expected to be collected. These specific allowances are re-evaluated and adjusted as additional information is received. The amounts calculated are analyzed to determine the total amount of the allowance. The Company may also record a general allowance as necessary. The Company’s management estimates its allowance for contractual pricing, by evaluating specific accounts where information indicates the customer is offered contractual pricing and discount allowances. In these arrangements, the Company’s management uses assumptions and judgement, based on the best available facts and circumstances to record a specific allowance for the amounts due from those customers. The allowance is offset by a corresponding reduction to revenue. These specific allowances are re-evaluated and adjusted as additional information is received. The amounts calculated are analyzed to determine the total amount of the allowance. The Company may also record a general allowance as necessary. Accounts deemed uncollectible are written-off in the period when the Company has exhausted its efforts to collect overdue and unpaid receivables or otherwise has evaluated other circumstances that indicate that the Company should abandon such efforts. Previously written-off accounts receivable subsequently collected are recognized as a reduction of bad debt expense when funds are received.
Inventories	Inventories are stated at the net realizable value (first-in, first-out). Inventories consist entirely of finished goods and include Orthopedic Implants and Biologics. The Company reviews the market value of inventories whenever events and circumstances indicate that the carrying value of inventories may not be recoverable from the estimated future sales price less cost of disposal and normal gross profit. In cases where the market values are less than the carrying value, a write-down is recognized equal to an amount by which the carrying value exceeds the market value of inventories.
Property and Equipment	Property and equipment are recorded at cost less accumulated depreciation and amortization. Depreciation and amortization are computed using the straight-line method over the estimated useful lives of the related assets per the following table. Leasehold improvements are amortized over the lesser of their useful life or the lease term. Expenditures for additions and improvements are capitalized while repairs and maintenance are expensed as incurred. Category Amortization Period Computer equipment 3 years Furniture and fixtures 3 years Office equipment 3 years Software 3 years Upon the retirement or disposition of property and equipment, the related cost and accumulated depreciation and amortization are removed and a gain or loss is recorded in the consolidated statements of operations.
Long-Lived Assets	The Company assesses potential impairment to its long-lived assets when there is evidence that events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Events and circumstances considered by the Company in determining whether the carrying value of identifiable intangible assets and other long-lived assets may not be recoverable include, but are not limited to: (i) significant changes in performance relative to expected operating results, (ii) significant changes in the use of the assets, (iii) significant negative industry or economic trends, (iv) a significant decline in the Company’s stock price for a sustained period of time, and (v) changes in the Company’s business strategy. An impairment loss is recorded when the carrying amount of the long-lived asset is not recoverable and exceeds its fair value. The carrying amount of a long-lived asset is not recoverable if it exceeds the sum of the undiscounted cash flows expected to result from the use and eventual disposition of the asset. Any required impairment loss is measured as the amount by which the carrying amount of a long-lived asset exceeds fair value and is recorded as a reduction in the carrying value of the related asset and an expense to operating results. Based upon the Company’s assessment, there were no indicators of impairment of its long-lived assets at December 31, 2017 and 2016.
Goodwill	Goodwill is the excess of the purchase price over the fair value of net assets of acquired businesses. Goodwill is tested for impairment annually or whenever an event occurs or circumstances change that would indicate that the carrying amount may be impaired. The test for impairment requires us to make several estimates about fair value, most of which are based on projected future cash flows. The Company’s management estimates associated with the goodwill impairment test are considered critical due to the amount of goodwill recorded on our consolidated balance sheets and the judgment required in determining fair value, including projected future cash flows. No goodwill impairment has been recognized during 2017 or 2016.
Revenue Recognition	The Company recognizes revenue when: (i) persuasive evidence of an arrangement exists; (ii) the fees are fixed or determinable; (iii) no significant Company obligations remain; and (iv) collection of the related receivable is reasonably assured. The Company reports revenues for transactions in which it is the primary obligor on a gross basis and revenues in which it acts as an agent (earning a fixed percentage of the sale) on a net basis, (net of related costs). The Company reports funds collected from customers as deferred revenues until all revenue recognition criteria have been met. Revenues are sales of Orthopedic Implants and Biologics to support orthopedic surgeries and wound care . For customers that purchase products as needed, Products that have been sold are not subject to returns unless the product is deemed defective. Credits or refunds are recognized when they are determinable and estimable. Net revenues have been reduced to account for sales returns, discounts and other incentives.
Cost of Revenues	Cost of revenues consists of cost of goods sold, freight and shipping costs for items sold to customers, cost of storage, and related supply chain costs.
Shipping and Handling Fees	The Company includes shipping and handling fees billed to customers in revenues and the related costs in cost of revenues.
Income Taxes	As a result of the CPM Acquisition, Fuse became the sole managing member of CPM and as a result, began consolidating the financial results of CPM. CPM is treated as a partnership for U.S. federal and most applicable state and local income tax purposes. As a partnership, CPM is not subject to U.S. federal and most applicable state and local income tax purposes. As a partnership, CPM is not subject to U.S. federal and certain state and local income taxes. Any taxable income or loss generated by CPM is passed through to an included in the taxable income or loss of its members. The Company uses the asset and liability method to compute the differences between the tax basis of assets and liabilities and the related financial amounts. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount that more likely than not will be realized. The Company has deferred tax assets and liabilities that reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Deferred tax assets are subject to periodic recoverability assessments. Realization of the deferred tax assets, net of deferred tax liabilities, is principally dependent upon achievement of projected future taxable income. The Company records a liability for uncertain tax positions when it is probable that a loss has been incurred and the amount can be reasonably estimated. As of December 31, 2017, the Company had no liabilities for uncertain tax positions. The Company's policy is to recognize interest and penalties related to income tax matters as a component of income tax expense. The Company continually evaluates expiring statutes of limitations, audits, proposed settlements, changes in tax law, and new authoritative rulings.
Segment Information	The Company operates in one reportable segment including medical products and supplies. The Company's chief operating decision maker, is its Chief Executive Officer. The Company’s Chief Executive Officer manages the Company's operations as a whole, and does not evaluate revenue, expense or operating income information on any component level.
Stock-Based Compensation	Stock-based compensation expense is measured at the grant date fair value of the award and is expensed over the requisite service period. For employee stock-based awards, the Company calculates the fair value of the award on the date of grant using the Black-Scholes option pricing model. Determining the fair value of stock-based awards at the grant date under this model requires judgment, including estimating volatility, employee stock option exercise behaviors and forfeiture rates. The assumptions used in calculating the fair value of stock-based awards represent the Company's best estimates, but these estimates involve inherent uncertainties and the application of management judgment. For non-employee stock-based awards, the Company calculates the fair value of the award on the date of grant in the same manner as employee awards, however, the awards are revalued at the end of each reporting period and the prorata compensation expense is adjusted accordingly until such time the non-employee award is fully vested, at which time the total compensation recognized to date shall equal the fair value of the stock-based award as calculated on the measurement date, which is the date at which the award recipient’s performance is complete. The estimation of stock-based awards that will ultimately vest requires judgment, and to the extent actual results or updated estimates differ from original estimates, such amounts are recorded as a cumulative adjustment in the period estimates are revised.
Recent Accounting Pronouncements	In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2014-09, “Revenue from Contracts with Customers”. ASU 2014-09 is a comprehensive revenue recognition standard that will supersede nearly all existing revenue recognition guidance under current GAAP and replace it with a principle-based approach for determining revenue recognition. ASU 2014-09 will require that companies recognize revenue based on the value of transferred goods or services as they occur in the contract. The ASU also will require additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments and assets recognized from costs incurred to obtain or fulfill a contract. ASU 2014-09 is effective for interim and annual periods beginning after December 15, 2017. Early adoption is permitted only in annual reporting periods beginning after December 15, 2016, including interim periods therein. Entities will be able to transition to the standard either retrospectively or as a cumulative-effect adjustment as of the date of adoption. The Company’s management is in the process of evaluating the impact of ASU 2014-09 on the Company's financial statements and disclosures. In July 2015, the FASB issued ASU No. 2015-11 — “Inventory (Topic 330)”, which requires an entity to measure inventory at the lower of cost and net realizable value. Net realizable value is the estimated selling price in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. The Company adopted ASU 2015-11 as of January 1, 2017 and did not have a material impact on the Company’s financial statements. In February 2016, the FASB issued Accounting Standards Update No. 2016-02, “Leases”, which requires a lessee to record a right of use asset and a corresponding lease liability on the balance sheet for all leases with terms longer than 12 months. ASU 2016-02 is effective for all interim and annual reporting periods beginning after December 15, 2018. Early adoption is permitted. A modified retrospective transition approach is required for lessees for capital and operating leases existing at, or entered after, the beginning of the earliest comparative period presented in the financial statements, with certain practical expedients available. The Company’s management is in the process of evaluating the impact of the adoption of ASU 2016-02 on the Company's financial statements and disclosures. In August 2016, the FASB issued ASU No. 2016-15, “Statement of Cash Flows (Topic 230) Classification of Certain Cash Receipts and Cash payments.” The update addresses eight specific cash flow issues with the objective of reducing the existing diversity in practice. This ASU is effective for the public business entities for fiscal years beginning after December 15, 2017 and for interim periods within those fiscal years. The amendments in this update may be applied retrospectively or prospectively and early adoption is permitted. The Company’s management In November 2016, the FASB issued ASU Update No. 2016-18 — “Statement of Cash Flows (Topic 230): Restricted Cash (A Consensus of the FASB EITF)”. ASU 2016-18 requires that a statement of cash flows explain the change during the period in the total of cash, cash equivalents, and amounts generally described as restricted cash or restricted cash equivalents. These amounts should be included with cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts shown on the statement of cash flows. This amendment does not provide a definition of restricted cash or restricted cash equivalents. The update will be effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2017. The Company’s management is in the process of evaluating the impact of ASU 2016-18 on the Company’s financial statements and disclosures. Other recent accounting pronouncements issued by the FASB, including its Emerging Issues Task Force, the American Institute of Certified Public Accountants, and the Securities and Exchange Commission, (the “SEC”) did not or are not believed by management to have a material impact on the Company's present or future consolidated financial statements.

Significant Accounting Polici20

Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2017
Accounting Policies [Abstract]
Estimated Useful Lives Of Assets	Category Amortization Period Computer equipment 3 years Furniture and fixtures 3 years Office equipment 3 years Software 3 years

Acquisition (Tables)

Acquisition (Tables)	12 Months Ended
	Dec. 31, 2017
Business Combinations [Abstract]
Unaudited Pro Forma Information	Unaudited pro forma information for the twelve months ended December 31, 2016 is as follows: Year Ended December 31, 2016 - Unaudited Historical Fuse Medical, Inc. Historical CPM Medical Consultants, LLC Pro forma Adjustments Pro forma Combined Revenue $ 567,607 $ 25,647,353 $ (103,578 ) $ 26,111,382 Net (loss) income $ (585,935 ) $ 3,035,296 $ - $ 2,449,361 Net (loss) income per common share - basic $ - $ - $ - $ 0.34

Property and Equipment (Tables)

Property and Equipment (Tables)	12 Months Ended
	Dec. 31, 2017
Property Plant And Equipment [Abstract]
Property and Equipment	Property and equipment consisted of the following at December 31, 2017 and 2016: December 31, 2017 December 31, 2016 Computer equipment $ - $ 29,290 Furniture and fixtures 5,047 6,347 Leasehold improvements - 6,728 Office equipment 21,913 9,221 Software - 34,252 26,960 85,838 Less: accumulated depreciation (10,065 ) (71,091 ) Property and equipment, net $ 16,895 $ 14,747

Notes Payable - Related Parti23

Notes Payable - Related Parties (Tables)	12 Months Ended
	Dec. 31, 2017
Debt Disclosure [Abstract]
Notes Payable in Related Parties	Notes payable – related parties consisted of the following: December 31, 2017 December 31, 2016 Notes Payable originating July 15, 2016; no monthly payments required; bearing interest at 10%; due on December 31, 2016, convertible on demand $ 50,000 $ 50,000 Notes Payable originating August 23, 2016; no monthly payments required; bearing interest at 10%; due on December 31, 2016, convertible on demand 50,000 50,000 Notes Payable originating October 19, 2016; no monthly payments required; bearing interest at 10%; due on December 31, 2016, convertible on demand 50,000 50,000 Total 150,000 150,000 Less: current maturities (150,000 ) (150,000 ) Amount due after one year $ - $ -

Commitments and Contingencies (

Commitments and Contingencies (Tables)	12 Months Ended
	Dec. 31, 2017
Commitments And Contingencies Disclosure [Abstract]
Summary of Operating Leases	The following is a schedule by years of future minimum rental payments required under operating leases that have initial or remaining noncancelable lease terms in excess of one year as of December 31, 2017: Year ending December 31, 2018 $ 9,000 2019 5,000 2020 3,000 2021 500 $ 17,500

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	12 Months Ended
	Dec. 31, 2017
Stockholders Equity Deficit Tables [Abstract]
Summary of Compensation Expense for Stock Options Granted to Employees	The following table summarizes the assumptions the Company utilized to record compensation expense for stock options granted to employees during the year ended December 31, 2016: Assumptions For the Year Ended December 31, 2017 For the Year Ended December 31, 2016 Expected term (years) - 2.5 Expected volatility 0 % 162 % Weighted-average volatility 0 % 162 % Risk-free interest rate 0.00 % 1.43 % Dividend yield 0.0 % 0.0 % Expected forfeiture rate n/a n/a
Summary of Stock Option Activity	A summary of the Company’s stock option activity during the year ended December 31, 2017 is presented below: No. of Shares Weighted Average Exercise Price Weighted Average Remaining Contractual Term Aggregate Intrinsic Value Balance outstanding at December 31, 2016 1,304,788 $ 0.22 Granted - $ - Exercised — $ - Forfeited — $ - Expired (2,736 ) $ 12.13 Balance outstanding at December 31, 2017 1,302,052 $ 0.20 3.3 $ 1,717,000 Exercisable at December 31, 2017 1,302,052 $ 0.20 3.3 $ 1,717,000
Summary of Restricted Common Stock Activity	The following table summarizes restricted common stock activity: Number of Shares Fair Value Weighted Average Grant Date Fair Value Non-vested, December 31, 2016 - $ - $ - Granted 3,267,500 1,813,500 0.56 Vested - - - Forfeited - - - Non-vested, December 31, 2017 3,267,500 $ 1,813,500 $ 0.56

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2017
Income Tax Disclosure [Abstract]
Components of Income Tax Expense (Benefit)	The components of income tax expense (benefit) are as follows: For the Year Ended December 31, 2017 For the Year Ended December 31, 2016 Current: Federal $ - $ - State 40,818 51,627 40,818 51,627 Deferred: Federal - - State - - - - Total Income tax expense (benefit) $ 40,818 $ 51,627
Significant Components of Deferred Income Tax Assets and Liabilities	Significant components of the Company's deferred income tax assets and liabilities are as follows: December 31, 2017 December 31, 2016 Deferred tax assets: Net operating loss carryover $ 172,704 $ 224,381 Intangibles 40,342 - Accounts receivable 81,927 - Compensation 57,458 80,850 Inventory 25,792 - Total deferred tax assets 378,223 305,231 Deferred tax liabilities: Prepaid expenses - - Property and equipment (2,945 ) 2,795 Total deferred tax liabilities (2,945 ) 2,795 Deferred tax assets, net 375,278 308,026 Valuation allowance: Beginning of year (308,026 ) (700,713 ) (Increase) decrease during year 308,026 392,687 Ending balance - (308,026 ) Net deferred tax asset $ 375,278 $ -
Reconciliation of Income Tax Computed at U.S. Statutory Rate to Effective Income Tax Rate	A reconciliation of income tax computed at the U.S. statutory rate to the effective income tax rate is as follows: For the Year Ended December 31, 2017 For the Year Ended December 31, 2016 Statutory U.S. federal income tax rate 35.0 % 35.0 % State income taxes, net of federal tax benefit 5.8 % 1.7 % Permanent differences 3.8 % 0.3 % Other reconciling items 20.5 % 19.8 % LLC flow-through structure (59.3 %) (42.1 %) Valuation allowance 0.0 % (13.0 %) Effective income tax rate 5.8 % 1.7 %

Concentrations (Tables)

Concentrations (Tables)	12 Months Ended
	Dec. 31, 2017
Revenues [Member]
Concentration Risk [Line Items]
Concentration of Revenues, Accounts Receivable and Suppliers	For the years ended December 31, 2017 and 2016, the following significant customers had an individual percentage of total revenues equaling 10% or greater: For the Year Ended December 31, 2017 For the Year Ended December 31, 2016 Customer 1 (related party) 18.70 % 18.33 % Customer 2 18.06 % 11.61 % Totals 36.76 % 29.94 %
Accounts Receivable [Member]
Concentration Risk [Line Items]
Concentration of Revenues, Accounts Receivable and Suppliers	At December 31, 2017 and 2016, the following significant customers had a concentration of accounts receivable representing 10% or greater of accounts receivable: December 31, 2017 December 31, 2016 Customer 1 (related party) 24.80 % 25.21 % Customer 2 15.26 % 12.92 % Totals 40.06 % 38.13 %
Goods Purchased [Member]
Concentration Risk [Line Items]
Concentration of Revenues, Accounts Receivable and Suppliers	For the years ended December 31, 2017 and 2016, the following significant suppliers represented 10% or greater of goods purchased: For the Year Ended December 31, 2017 For the Year Ended December 31, 2016 Supplier 1 22.34 % 22.36 % Totals 22.34 % 22.36 %

Nature of Operations (Details N

Nature of Operations (Details Narrative) - USD ($)	Dec. 29, 2017	Dec. 19, 2016	Oct. 31, 2016	Dec. 31, 2017	Dec. 31, 2016
Nature Of Operations And Going Concern [Line Items]
Convertible notes payable - related parties				$ 150,000	$ 150,000
Direct offering costs		$ 64,609
Net proceeds from sale of common stock		$ 655,391
Common Stock Par Value				$ 0.01	$ 0.01
CPM [Member]
Nature Of Operations And Going Concern [Line Items]
Date of acquisition agreement	Dec. 29, 2017
Number of shares issued for acquisition	50,000,000
Common Stock Par Value	$ 0.01
Equity interest percentage	100.00%
Business acquisition share price	$ 0.20
Effective date of acquisition	Dec. 31, 2017
NC 143 Family Holdings, LP [Member]
Nature Of Operations And Going Concern [Line Items]
Sale of common shares		5,000,000
Gross proceeds from sale of common shares		$ 400,000
RMI [Member]
Nature Of Operations And Going Concern [Line Items]
Sale of common shares		4,000,000
Gross proceeds from sale of common shares		$ 320,000
10% Convertible Promissory Notes [Member]
Nature Of Operations And Going Concern [Line Items]
Convertible notes payable - related parties			$ 150,000
Interest rate of promissory notes			10.00%
Conversion price of common stock			$ 0.08
10% Convertible Promissory Notes [Member] | NC 143 Family Holdings, LP [Member]
Nature Of Operations And Going Concern [Line Items]
Convertible notes payable - related parties			$ 100,000
10% Convertible Promissory Notes [Member] | RMI [Member]
Nature Of Operations And Going Concern [Line Items]
Convertible notes payable - related parties			$ 50,000

Significant Accounting Polici29

Significant Accounting Policies (Details Narrative)	12 Months Ended
	Dec. 31, 2017USD ($)Segmentshares	Dec. 31, 2016USD ($)shares
Significant Accounting Policies [Line Items]
Outstanding common stock equivalents included with diluted net earnings per share | shares	700,000
Options to purchase included in common stock equivalents | shares	1,302,052	1,304,788
Earn-out liability	$ 19,244,543
Cash equivalents	0	$ 0
FDIC insurance limit	250,000
Deposits greater than federally insured limit	537,388	421,636
Goodwill impairment	0	$ 0
Liabilities for uncertain tax positions, current	0
liabilities for uncertain tax positions, noncurrent	$ 0
Number of reportable segments | Segment	1
CPM [Member]
Significant Accounting Policies [Line Items]
Earn-out liability	$ 19,244,543

Significant Accounting Polici30

Significant Accounting Policies - Estimated Useful Lives of Assets (Details)	12 Months Ended
	Dec. 31, 2017
Computer equipment [Member]
Property Plant And Equipment [Line Items]
Estimated useful lives of the assets	3 years
Furniture and fixtures [Member]
Property Plant And Equipment [Line Items]
Estimated useful lives of the assets	3 years
Office equipment [Member]
Property Plant And Equipment [Line Items]
Estimated useful lives of the assets	3 years
Software [Member]
Property Plant And Equipment [Line Items]
Estimated useful lives of the assets	3 years

Acquisition (Details Narrative)

Acquisition (Details Narrative)	Dec. 29, 2017USD ($)$ / sharesshares	Dec. 19, 2016USD ($)shares	Oct. 19, 2016	Aug. 23, 2016	Jul. 15, 2016	Oct. 31, 2016USD ($)Loan$ / shares	Dec. 31, 2017USD ($)Segment$ / sharesshares	Dec. 31, 2016USD ($)$ / sharesshares
Business Acquisition [Line Items]
Notes payable - related parties							$ 150,000	$ 150,000
Direct offering costs		$ 64,609
Net proceeds from sale of common stock		655,391
Percentage of common stock issued							61.40%
Percentage of common stock outstanding							61.40%
Goodwill		$ 820,000					$ 820,650	$ 820,650
Common Stock Par Value | $ / shares							$ 0.01	$ 0.01
Adjustment of supplemental pro forma earnings								$ (26,111,382)
Number of shares outstanding calculated the net (loss) per common share – basic | shares							16,027,794	7,185,890
Number of operating segments | Segment							1
Pro forma Adjustment [Member]
Business Acquisition [Line Items]
Adjustment of supplemental pro forma earnings								$ 103,578
Common Stock [Member]
Business Acquisition [Line Items]
Sale of common shares | shares								9,000,000
CPM [Member]
Business Acquisition [Line Items]
Date of acquisition agreement	Dec. 29, 2017
Number of shares issued for acquisition | shares	50,000,000
Common Stock Par Value | $ / shares	$ 0.01
Equity interest percentage	100.00%
Share price | $ / shares	$ 0.20
Effective date of acquisition	Dec. 31, 2017
Acquisition additional one-time costs	$ 200,000
Fair value of earn-out payments							$ 19,244,543
Adjustment of supplemental pro forma earnings								$ (25,647,353)
CPM [Member] | Common Stock [Member]
Business Acquisition [Line Items]
Number of shares issued for acquisition | shares	50,000,000
Common Stock Par Value | $ / shares	$ 0.01
Equity interest percentage	100.00%
Share price | $ / shares	$ 0.20
Post-closing adjustment will be paid in shares							$ 397,463
Period for post- closing adjustment payment							120 days
NC 143 Family Holdings, LP [Member]
Business Acquisition [Line Items]
Sale of common shares | shares		5,000,000
Gross proceeds from sale of common shares		$ 400,000
NC 143 Family Holdings, LP [Member] | Common Stock [Member]
Business Acquisition [Line Items]
Sale of common shares | shares		5,000,000
Gross proceeds from sale of common shares		$ 400,000
RMI [Member]
Business Acquisition [Line Items]
Sale of common shares | shares		4,000,000
Gross proceeds from sale of common shares		$ 320,000
RMI [Member] | Common Stock [Member]
Business Acquisition [Line Items]
Sale of common shares | shares		4,000,000
Gross proceeds from sale of common shares		$ 320,000
NC 143 Family Holdings, LP and RMI [Member] | CPM [Member]
Business Acquisition [Line Items]
Percentage of common stock outstanding							90.40%
10% Promissory Notes [Member]
Business Acquisition [Line Items]
Number of loans obtained | Loan						3
Notes payable - related parties						$ 150,000
Interest rate of promissory notes			10.00%	10.00%	10.00%	10.00%
Conversion price of common stock | $ / shares						$ 0.08
10% Promissory Notes [Member] | NC 143 Family Holdings, LP [Member]
Business Acquisition [Line Items]
Notes payable - related parties						$ 100,000
10% Promissory Notes [Member] | RMI [Member]
Business Acquisition [Line Items]
Notes payable - related parties						$ 50,000

Acquisition - Unaudited Pro For

Acquisition - Unaudited Pro Forma Information (Details)	12 Months Ended
	Dec. 31, 2016USD ($)$ / shares
Business Acquisition Pro Forma Information [Line Items]
Revenue	$ 26,111,382
Net (loss) income	$ 2,449,361
Net (loss) income per common share - basic | $ / shares	$ 0.34
Historical Fuse Medical, Inc [Member]
Business Acquisition Pro Forma Information [Line Items]
Revenue	$ 567,607
Net (loss) income	(585,935)
Pro forma Adjustment [Member]
Business Acquisition Pro Forma Information [Line Items]
Revenue	(103,578)
Historical CPM Medical Consultants, LLC [Member]
Business Acquisition Pro Forma Information [Line Items]
Revenue	25,647,353
Net (loss) income	$ 3,035,296

Property and Equipment (Details

Property and Equipment (Details) - USD ($)	Dec. 31, 2017	Dec. 31, 2016
Property Plant And Equipment [Line Items]
Property and equipment, gross	$ 26,960	$ 85,838
Less: accumulated depreciation	(10,065)	(71,091)
Property and equipment, net	16,895	14,747
Computer equipment [Member]
Property Plant And Equipment [Line Items]
Property and equipment, gross		29,290
Furniture and fixtures [Member]
Property Plant And Equipment [Line Items]
Property and equipment, gross	5,047	6,347
Leasehold improvements [Member]
Property Plant And Equipment [Line Items]
Property and equipment, gross		6,728
Office equipment [Member]
Property Plant And Equipment [Line Items]
Property and equipment, gross	$ 21,913	9,221
Software [Member]
Property Plant And Equipment [Line Items]
Property and equipment, gross		$ 34,252

Property and Equipment (Detai34

Property and Equipment (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Property Plant And Equipment [Abstract]
Sale of property and equipment	$ 607
Proceeds from the disposal of property and equipment	300
Retired fixed assets no longer use with net book value	3,058
Proceeds from insurance settlement for fully depreciated fixed asset	8,732
Depreciation expense	$ 14,521	$ 19,091

Revolving Line of Credit (Detai

Revolving Line of Credit (Details Narrative) - CPM [Member] - USD ($)	Dec. 29, 2017	Dec. 31, 2017	Dec. 31, 2016
Debt Instrument [Line Items]
Date of acquisition agreement	Dec. 29, 2017
Effective date of acquisition	Dec. 31, 2017
Senior Secured Revolving Credit Facility [Member] | ZB, N.A. (d/b/a Amegy Bank) [Member]
Debt Instrument [Line Items]
Line of credit maximum borrowing capacity	$ 5,000,000
RLOC [Member] | ZB, N.A. (d/b/a Amegy Bank) [Member]
Debt Instrument [Line Items]
Date of acquisition agreement	Dec. 29, 2017
Effective date of acquisition		Dec. 31, 2017
Effective rate		4.56%
Variable rate, description		one-month LIBOR rate plus 3.00%
Variable rate		3.00%
Percentage of guarantees of outstanding loan amount		50.00%
Line of credit outstanding balance amount		$ 3,415,351	$ 3,305,347
Interest expense		$ 134,668	$ 133,334

Notes Payable - Related Parti36

Notes Payable - Related Parties (Details Narrative) - USD ($)	Oct. 19, 2016	Aug. 23, 2016	Jul. 15, 2016	Oct. 31, 2016	Dec. 31, 2017	Dec. 31, 2016
Debt Instrument [Line Items]
Convertible notes payable - related parties					$ 150,000	$ 150,000
Aggregate amount of beneficial conversion feature				$ 117,500
Interest expense on notes payable					27,000	13,587
Amortization of beneficial conversion feature						13,094
Accrued expenses [Member]
Debt Instrument [Line Items]
Accrued interest payable					$ 32,096	$ 5,096
10% Promissory Notes [Member]
Debt Instrument [Line Items]
Convertible notes payable - related parties				$ 150,000
Interest rate of promissory notes	10.00%	10.00%	10.00%	10.00%
Debt Instrument, description					principal shall be due and payable, upon demand of the payee. Notwithstanding, at the holder’s sole discretion, the holder has the right to convert all or any portion of the then unpaid principal and interest balance into shares of the Company’s common stock at a conversion price of $0.08 per share. On each respective date of issuance, the conversion price of each of the promissory notes was less than the market price of the Company’s common stock.
Conversion price of common stock				$ 0.08

Notes Payable - Related Parti37

Notes Payable - Related Parties (Details) - USD ($)	Dec. 31, 2017	Dec. 31, 2016	Oct. 31, 2016
Debt Instrument [Line Items]
Total notes payable	$ 150,000	$ 150,000
Less: current maturities	(150,000)	(150,000)
10% Promissory Notes [Member]
Debt Instrument [Line Items]
Less: current maturities			$ (150,000)
10% Promissory Notes [Member] | Originating July 15, 2016 [Member]
Debt Instrument [Line Items]
Total notes payable	50,000	50,000
10% Promissory Notes [Member] | Originating August 23, 2016 [Member]
Debt Instrument [Line Items]
Total notes payable	50,000	50,000
10% Promissory Notes [Member] | Originating October 19, 2016 [Member]
Debt Instrument [Line Items]
Total notes payable	$ 50,000	$ 50,000

Notes Payable - Related Parti38

Notes Payable - Related Parties (Parenthetical) (Details)	Oct. 19, 2016	Aug. 23, 2016	Jul. 15, 2016	Oct. 31, 2016
10% Promissory Notes [Member]
Debt Instrument [Line Items]
Interest rate of promissory notes	10.00%	10.00%	10.00%	10.00%

Commitments and Contingencies39

Commitments and Contingencies (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Commitments And Contingencies [Line Items]
Loss contingency, complaint filing date	January 27, 2014
Loss contingency, name of plaintiff	M. Richard Cutler and Cutler Law Group, P.C.
Loss contingency, name of defendants	Fuse, Alan Meeker, Rusty Shelton, Jonathan Brown, Robert H. Donehew and Golf Rounds.com, Inc.
Loss contingency, date of complaint dismissal	Apr. 21, 2014
Plaintiffs claim Defendants for damages	$ 46,465
Lease termination date	Dec. 31, 2017
Operating lease requires monthly payments	$ 14,000
Office Equipment One [Member]
Commitments And Contingencies [Line Items]
Operating lease expiration month and year	2019-03
Office Equipment Two [Member]
Commitments And Contingencies [Line Items]
Operating lease expiration month and year	2021-02
Office Equipment Leases [Member]
Commitments And Contingencies [Line Items]
Operating lease requires monthly payments	$ 779
Selling, General, Administrative and Other Expenses [Member]
Commitments And Contingencies [Line Items]
Annual rent expense	142,000	$ 120,000
Selling, General, Administrative and Other Expenses [Member] | Office Equipment Leases [Member]
Commitments And Contingencies [Line Items]
Annual rent expense	$ 11,000	$ 8,000
PH Squared, LLC for Breach of Contract [Member] | Pending Litigation [Member]
Commitments And Contingencies [Line Items]
Loss contingency, complaint filing date	November 18, 2015
Loss contingency, scheduled trial date	May 1, 2017
Loss contingency, postponed trial date	Jul. 24, 2017

Commitments and Contingencies -

Commitments and Contingencies - Summary of Operating Leases (Details)	Dec. 31, 2017USD ($)
Commitments And Contingencies Disclosure [Abstract]
2,018	$ 9,000
2,019	5,000
2,020	3,000
2,021	500
Total	$ 17,500

Stockholders' Equity (Details N

Stockholders' Equity (Details Narrative) - USD ($)	Dec. 29, 2017	Dec. 14, 2017	Sep. 21, 2017	Dec. 19, 2016	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2016	Oct. 04, 2017	Apr. 05, 2017
Class Of Stock [Line Items]
Common Stock Shares Authorized					100,000,000	100,000,000	100,000,000
Common Stock Par Value					$ 0.01	$ 0.01	$ 0.01
Preferred Stock Shares Authorized					20,000,000	20,000,000	20,000,000
Preferred Stock Par Value					$ 0.01	$ 0.01	$ 0.01
Direct offering costs				$ 64,609
Net proceeds from sale of common stock				$ 655,391
Weighted-average grant-date fair value of options granted during the year							$ 0.09
Stock Option [Member]
Class Of Stock [Line Items]
Stock options					0
Restricted Stock Award [Member]
Class Of Stock [Line Items]
Fair market value of each common stock					$ 0.56
Number of common stock granted					3,267,500
2017 Plan [Member] | Restricted Stock Award [Member]
Class Of Stock [Line Items]
Number of shares of common stock authorized for issuance			325,000
Fair market value of each common stock			$ 0.78
Vesting description					Fully vest upon the one-year anniversary of the date of grant or September 21, 2018.
Vesting period of RSA			1 year
Number of common stock granted			2,000,000
2017 Plan [Member] | Restricted Stock Award [Member] | Each Member of Board [Member]
Class Of Stock [Line Items]
Unrecognized compensation expenses					$ 43,336
2017 Plan [Member] | Restricted Stock Award [Member] | Each Member of Board [Member] | Selling, General and Administrative Expenses [Member]
Class Of Stock [Line Items]
Share-based compensation expense					21,664
2017 Plan [Member] | Restricted Stock Award [Member] | Independent Directors [Member]
Class Of Stock [Line Items]
Share-based compensation expense					0
NC 143 Family Holdings, LP [Member]
Class Of Stock [Line Items]
Sale of common shares				5,000,000
Gross proceeds from sale of common shares				$ 400,000
RMI [Member]
Class Of Stock [Line Items]
Sale of common shares				4,000,000
Gross proceeds from sale of common shares				$ 320,000
Common Stock [Member]
Class Of Stock [Line Items]
Sale of common shares						9,000,000
Common Stock [Member] | 2017 Plan [Member]
Class Of Stock [Line Items]
Number of shares of common stock authorized for issuance			2,500,000					4,500,000	1,500,000
Common Stock [Member] | 2017 Plan [Member] | Restricted Stock Award [Member]
Class Of Stock [Line Items]
Number of common stock granted		942,500
Common Stock [Member] | 2017 Plan [Member] | Restricted Stock Award [Member] | Each Member of Board [Member]
Class Of Stock [Line Items]
Fair market value of each common stock		$ 0.20
Unrecognized compensation expenses					167,555
Number of common stock granted		188,500
Common Stock [Member] | 2017 Plan [Member] | Restricted Stock Award [Member] | Each Member of Board [Member] | Selling, General, Administrative and Other Expenses [Member]
Class Of Stock [Line Items]
Share-based compensation expense					$ 20,945
Common Stock [Member] | NC 143 Family Holdings, LP [Member]
Class Of Stock [Line Items]
Sale of common shares				5,000,000
Gross proceeds from sale of common shares				$ 400,000
Common Stock [Member] | RMI [Member]
Class Of Stock [Line Items]
Sale of common shares				4,000,000
Gross proceeds from sale of common shares				$ 320,000
Common Stock [Member] | Mark W. Brooks and Christopher C. Reeg [Member]
Class Of Stock [Line Items]
Direct offering costs				64,609
Net proceeds from sale of common stock				$ 655,391
CPM [Member]
Class Of Stock [Line Items]
Common Stock Par Value	$ 0.01
Date of acquisition agreement	Dec. 29, 2017
Number of shares issued for acquisition	50,000,000
Equity interest percentage	100.00%
Share price	$ 0.20
Effective date of acquisition	Dec. 31, 2017
CPM [Member] | Common Stock [Member]
Class Of Stock [Line Items]
Common Stock Par Value	$ 0.01
Number of shares issued for acquisition	50,000,000
Equity interest percentage	100.00%
Share price	$ 0.20

Stockholders' Equity - Summary

Stockholders' Equity - Summary of Compensation Expense for Stock Options Granted to Employees (Details)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Expected term (years)		2 years 6 months
Expected volatility	0.00%	162.00%
Weighted-average volatility	0.00%	162.00%
Risk-free interest rate	0.00%	1.43%
Dividend yield	0.00%	0.00%

Stockholders' Equity - Summar43

Stockholders' Equity - Summary of Stock Option Activity (Details)	12 Months Ended
	Dec. 31, 2017USD ($)$ / sharesshares
No. of shares, Abstract
No. of Shares, Beginning Balance | shares	1,304,788
Expired, No. Of Shares | shares	(2,736)
No. of Shares, Ending Balance | shares	1,302,052
Exercisable, No. Of Shares | shares	1,302,052
Weighted average exercise price, Abstract
Weighted Average Exercise Price, Beginning Balance | $ / shares	$ 0.22
Expired, Weighted Average Exercise Price | $ / shares	12.13
Weighted Average Exercise Price, Ending Balance | $ / shares	0.20
Exercisable, Weighted Average Exercise Price | $ / shares	$ 0.20
Weighted average remaining contractual term, Abstract
Weighted Average Remaining Contractual Term, Balance outstanding	3 years 3 months 18 days
Weighted Average Remaining Contractual Term, Exercisable	3 years 3 months 18 days
Aggregate intrinsic value, Abstract
Aggregate Intrinsic Value, Balance outstanding | $	$ 1,717,000
Aggregate Intrinsic Value, Exercisable | $	$ 1,717,000

Stockholders' Equity - Summar44

Stockholders' Equity - Summary of Restricted Common Stock Activity (Details) - Restricted Stock Award [Member]	12 Months Ended
	Dec. 31, 2017USD ($)$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Number of common stock granted | shares	3,267,500
Number of Shares, Non-vested, Ending Balance | shares	3,267,500
Share-based Compensation Arrangement by Share Based Payment Award, Equity Instruments Other than Options, Nonvested, Fair Value [Abstract]
Fair Value,Granted | $	$ 1,813,500
Fair Value, Non-vested, Ending Balance | $	$ 1,813,500
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]
Weighted Average Grant Date Fair Value,Granted | $ / shares	$ 0.56
Weighted Average Grant Date Fair Value, Non-vested, Ending Balance | $ / shares	$ 0.56

Income Taxes - Components of In

Income Taxes - Components of Income Tax Expense (Benefit) (Details) - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Current:
Federal	$ 0	$ 0
State	40,818	51,627
Total	40,818	51,627
Deferred:
Federal	0	0
State	0	0
Total	0	0
Total Income tax expense (benefit)	$ 40,818	$ 51,627

Income Taxes - Significant Comp

Income Taxes - Significant Components of Deferred Income Tax Assets and Liabilities (Details) - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Deferred tax assets:
Net operating loss carryover	$ 172,704	$ 224,381
Intangibles	40,342
Accounts receivable	81,927
Compensation	57,458	80,850
Inventory	25,792
Total deferred tax assets	378,223	305,231
Deferred tax liabilities:
Prepaid expenses	0	0
Property and equipment	(2,945)
Total deferred tax liabilities	(2,945)
Property and equipment		2,795
Total deferred tax liabilities		2,795
Deferred tax assets, net	375,278	308,026
Valuation allowance:
Beginning of year	(308,026)	(700,713)
(Increase) decrease during year	308,026	392,687
Ending balance		(308,026)
Net deferred tax asset	$ 375,278	$ 0

Income Taxes (Details Narrative

Income Taxes (Details Narrative)	12 Months Ended
	Dec. 31, 2017USD ($)
Income Tax Disclosure [Abstract]
Net operating loss carryforwards	$ 822,399
Net operating loss carryforwards earliest expiration year	2,018
Net operating loss carryforwards latest expiration year	2,037

Income Taxes - Reconciliation o

Income Taxes - Reconciliation of Income Tax Computed at U.S. Statutory Rate to Effective Income Tax Rate (Details)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Income Tax Disclosure [Abstract]
Statutory U.S. federal income tax rate	35.00%	35.00%
State income taxes, net of federal tax benefit	5.80%	1.70%
Permanent differences	3.80%	0.30%
Other reconciling items	20.50%	19.80%
LLC flow-through structure	(59.30%)	(42.10%)
Valuation allowance	0.00%	(13.00%)
Effective income tax rate	5.80%	1.70%

Concentrations - Significant Cu

Concentrations - Significant Customers with Individual Percentage of Total Revenues Equaling 10% or Greater (Details) - Revenues [Member] - Customer Concentration Risk [Member]	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Concentration Risk [Line Items]
Concentration risk, percentage	36.76%	29.94%
Customer 1 (Related Party) [Member]
Concentration Risk [Line Items]
Concentration risk, percentage	18.70%	18.33%
Customer 2 [Member]
Concentration Risk [Line Items]
Concentration risk, percentage	18.06%	11.61%

Concentrations - Significant 50

Concentrations - Significant Customers with Concentration of Accounts Receivable Representing 10% or Greater of Accounts Receivable (Details) - Accounts Receivable [Member] - Customer Concentration Risk [Member]	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Concentration Risk [Line Items]
Concentration risk, percentage	40.06%	38.13%
Customer 1 (Related Party) [Member]
Concentration Risk [Line Items]
Concentration risk, percentage	24.80%	25.21%
Customer 2 [Member]
Concentration Risk [Line Items]
Concentration risk, percentage	15.26%	12.92%

Concentrations - Significant Su

Concentrations - Significant Suppliers Represented 10% or Greater of Goods Purchased (Details) - Goods Purchased [Member] - Supplier Concentration Risk [Member]	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Concentration Risk [Line Items]
Concentration risk, percentage	22.34%	22.36%
Supplier 1 [Member]
Concentration Risk [Line Items]
Concentration risk, percentage	22.34%	22.36%

Related Party Transactions (Det

Related Party Transactions (Details Narrative)	Dec. 29, 2017$ / sharesshares	Oct. 31, 2016USD ($)$ / shares	Dec. 31, 2017USD ($)ft²Stockholder$ / shares	Dec. 31, 2016USD ($)$ / shares	Mar. 26, 2018FullTimeEquivalent
Related Party Transaction [Line Items]
Notes issued to related party			$ 150,000	$ 150,000
Number of primary stockholders | Stockholder			2
Percentage of common stock issued			61.40%
Percentage of common stock outstanding			61.40%
Common stock par value per share | $ / shares			$ 0.01	$ 0.01
Lease termination date			Dec. 31, 2017
Net sales to related parties			$ 1,055,000	$ 396,000
Purchases from related parties			128,000	8,000
Account Receivables [Member]
Related Party Transaction [Line Items]
Due from related parties			169,000	159,000
Commission [Member]
Related Party Transaction [Line Items]
Expense incurred on behalf of related parties			248,000	702,000
Selling, General and Administrative Expenses [Member]
Related Party Transaction [Line Items]
Expense incurred on behalf of related parties			$ 33,000	114,000
CPM [Member]
Related Party Transaction [Line Items]
Date of acquisition agreement	Dec. 29, 2017
Number of shares issued for acquisition | shares	50,000,000
Common stock par value per share | $ / shares	$ 0.01
Equity interest percentage	100.00%
Share price | $ / shares	$ 0.20
Effective date of acquisition	Dec. 31, 2017
1565 North Central Expressway, LP [Member]
Related Party Transaction [Line Items]
Area of leased property | ft²			11,500
Lease termination date			Dec. 31, 2017
AmBio Staffing, LLC [Member]
Related Party Transaction [Line Items]
Due to related parties			$ 112,000	107,000
AmBio Staffing, LLC [Member] | Selling, General and Administrative Expenses [Member]
Related Party Transaction [Line Items]
Fees paid for services			162,000	162,000
AmBio Staffing, LLC [Member] | Subsequent Event [Member]
Related Party Transaction [Line Items]
Number of full time equivalents supporting operations | FullTimeEquivalent					74
Number of full time equivalents directly supporting company | FullTimeEquivalent					42
Number of full time equivalents supporting other companies | FullTimeEquivalent					19
Number of full time equivalents shares with other companies | FullTimeEquivalent					13
MedUSA Group, LLC [Member]
Related Party Transaction [Line Items]
Net sales to related parties			5,054,000	4,797,000
MedUSA Group, LLC [Member] | Account Receivables [Member]
Related Party Transaction [Line Items]
Due from related parties			1,684,000	1,752,000
MedUSA Group, LLC [Member] | Commission [Member]
Related Party Transaction [Line Items]
Expense incurred on behalf of related parties			962,000	642,000
Texas Overlord, LLC [Member]
Related Party Transaction [Line Items]
Net sales to related parties			1,953,000	0
Texas Overlord, LLC [Member] | Account Receivables [Member]
Related Party Transaction [Line Items]
Due from related parties			444,000	0
Texas Overlord, LLC [Member] | Commission [Member]
Related Party Transaction [Line Items]
Expense incurred on behalf of related parties			101,000	0
N.B.M.J., Inc. [Member]
Related Party Transaction [Line Items]
Net sales to related parties			162,000	715,000
N.B.M.J., Inc. [Member] | Account Receivables [Member]
Related Party Transaction [Line Items]
Due from related parties			0	47,000
N.B.M.J., Inc. [Member] | Commission [Member]
Related Party Transaction [Line Items]
Expense incurred on behalf of related parties			0	0
Maxim Surgical, LLC [Member]
Related Party Transaction [Line Items]
Net sales to related parties			202,000	164,000
Purchases from related parties			468,000	458,000
Maxim Surgical, LLC [Member] | Account Receivables [Member]
Related Party Transaction [Line Items]
Due from related parties			50,000	45,000
Maxim Surgical, LLC [Member] | Account Payables [Member]
Related Party Transaction [Line Items]
Due to related parties			93,000	102,000
Sintu, LLC [Member] | Commission [Member]
Related Party Transaction [Line Items]
Expense incurred on behalf of related parties			$ 1,114,000	$ 692,000
10% Convertible Promissory Notes [Member]
Related Party Transaction [Line Items]
Notes issued to related party		$ 150,000
Interest rate of promissory notes		10.00%
Conversion price of common stock | $ / shares		$ 0.08
Debt Instrument, description			principal due and payable, upon demand of the payee. The Notes were issued as follows: $100,000 to NC 143 Family Holdings, LP, a family limited partnership controlled by Mark W. Brooks (“NC 143”), our Chairman of the Board of Directors (the “Board”); and $50,000 to Reeg Medical Industries, Inc., an investment holding company owned and controlled by Christopher C. Reeg, our Chief Executive Officer (“RMI”, and together with NC 143, the “Investors”). The Investors have the sole discretion and right to convert all or any portion of the then unpaid principal and interest balance of the Notes into shares of our common stock at a conversion price of $0.08 per share.
10% Convertible Promissory Notes [Member] | NC 143 [Member]
Related Party Transaction [Line Items]
Notes issued to related party		$ 100,000
10% Convertible Promissory Notes [Member] | RMI [Member]
Related Party Transaction [Line Items]
Notes issued to related party		$ 50,000

Subsequent Events (Details Narr

Subsequent Events (Details Narrative) - Collaborative Arrangement - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Subsequent Event [Line Items]
Distribution Term	2 years
Prior notice for agreement termination term	90 days
Revenue from sales and distribution	$ 4.3	$ 4.9
Percentage of total revenues	16.00%	19.00%